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ABSTRACT 
 
 
XLF-DEPENDENT NONHOMOLOGOUS END JOINING OF COMPLEX DNA DOUBLE-STRAND BREAKS WITH 
PROXIMAL THYMINE GLYCOL AND SCREENING FOR XRCC4-XLF INTERACTION INHIBITORS 
By Mohammed Al Mohaini, M.S. Pharmacology and Toxicology 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy 
at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2015 
 
Advisor: Lawrence F. Povirk, Professor, Department of Pharmacology and Toxicology 
 
DNA double-strand breaks induced by ionizing radiation are often accompanied by ancillary 
oxidative base damage that may prevent or delay their repair.   In order to better define the features that 
make some DSBs repair-resistant, XLF-dependent nonhomologous end joining of blunt-ended DSB 
substrates having the oxidatively modified nonplanar base thymine glycol (Tg) at the first (Tg1) , second 
(Tg2), third (Tg3) or fifth (Tg5) positions from one 3’ terminus was examined in human whole-cell extracts.  
Tg at the third position had little effect on end-joining even when present on both ends of the break.  
However, Tg as the terminal or penultimate base was a major barrier to end joining (>10-fold reduction 
in ligated products) and an absolute barrier when present at both ends. Dideoxy trapping of base excision 
repair intermediates indicated that Tg was excised from Tg1, Tg2 and Tg3 largely if not exclusively after 
DSB ligation.  However, Tg was rapidly excised from the Tg5 substrate, resulting in a reduced level of DSB 
 
 
 
xii 
 
ligation, as well as slow concomitant resection of the opposite strand. XLFL115D mutant completely 
eliminates ligation of all five substrates and previous X-ray crystallography shows that XLF binds to XRCC4 
via a “leucine lock” motif wherein L115 of XLF slips into a hydrophobic pocket in XRCC4. This makes the 
XRCC4-XLF interaction a good target to develop peptide inhibitors in order to radiosensitize breast tumor 
cells that are dependent on NHEJ to repair their DSBs after ionizing radiation exposure. Using mRNA 
display, we created a diverse library of 870 billion unique peptide sequences. After seven rounds of in 
vitro selection, the eluted fusions were cloned and sequenced. The results showed homology of 
sequences of five main families. We have selected representative peptides from those families (Pep 7.1-
7.5), and several were chemically synthesized.  However, none of these significantly inhibited XLF-
dependent end joining in whole-cell extracts. Overall, the results suggest that promoting ligation of DSBs 
with proximal base damage may be an important function of XLF, but that Tg can still be a major 
impediment to repair, being relatively resistant to both trimming and ligation.  The effectiveness of XLF-
XLRCC4 inhibitors in blocking nonhomologous end joining remains to be determined. 
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1. INTRODUCTION 
 
1.1 DNA Damage 
DNA damage can arise from endogenous and exogenous sources. There are different forms of 
DNA damage such as intrastrand crosslinks, interstrand crosslinks, base lesions, DNA single-strand breaks 
(SSBs), and DNA double-strand breaks (DSBs) (Lindahl, 1993).  DSBs are the most deleterious lesions 
among all forms of DNA damage and they are characterized by a breakage in the sugar phosphate 
backbone of both DNA strands. The sources of DNA DSBs include ionizing radiation (IR), radiomimetic 
drugs (e.g. bleomycin and neocarzinostatin), oxidative stress, topoisomerase poisons, and cellular 
processes such as V(D)J recombination, class-switch recombination and stalled replication forks (Povirk, 
2012; Kasten and Bartek, 2004). Unrepaired DNA DSBs can lead to cell death whereas mis-repaired DNA 
DSBs can result in mutation, chromosomal translocation, genomic instability and cancer (Alberto & 
Stephan, 2010).   
1.2 Ionizing Radiation 
Ionizing radiation (IR) is an essential part in the treatment of many types of cancer. 
Electromagnetic radiation such as X- and γ-rays and particulate radiation such as electrons, protons, alpha-
particles, heavy charged ions and neutrons can cause DNA damage through direct and indirect actions 
(Han and Yu, 2009). The direct pathway is through a direct interaction with DNA to cause ionization that 
results in biological changes. The indirect pathway is through the ionization of atoms or molecules, mainly 
water, in cells to form free radicals, which interact with and damage DNA.  Free radicals are highly reactive, 
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and they are formed when water inside a cell absorbs the deposited energy and rapidly produces oxidizing 
and reducing reactive hydroxyl radicals (•OH) that interact with DNA and induce damage.  
In general, IR causes base damages, SSBs and DSBs. Damage to nucleotide bases can be repaired 
by the base excision repair pathway, which also repairs SSBs (von Sonntag, 1987). However, the dominant 
and most serious DNA damage after an exposure to ionizing radiation is DSB which can be repaired by 
homologous recombination (HR) and non-homologous end joining (NHEJ). Nevertheless, IR can cause 
“clustered” damages that include SSBs or DSBs in addition to base damages, or multiple DSBs at different 
closely adjacent positions (Nikjoo et al., 1999; Boudaiffa et al., 2000). It is also very important to 
differentiate between the DNA damage produced exogenously by IR and that produced endogenously by 
reactive oxygen species (ROS) such as O2-, H2O2 and •OH which resulted from normal cellular metabolism 
(Wiseman & Hall, 1996; Ward, 1998). While both IR and ROS produce damaged termini such as 3’-
phosphate, the dominant DNA damage induced by ROS are base damage and SSBs, with about 0.5% of 
the generated damage being DSBs. The distribution of DSBs induced by ROS throughout the DNA appears 
to be “uniform” to some extent. However, IR produces complex lesions with clustered damages as a result 
of heterogeneous energy deposition by IR (Han and Yu, 2009). 
The free radicals produced by IR generate blocked termini such as 3′-phosphoglycolate (3′-PG), 
3′-phosphoglycoaldehyde, 3′-formyl phosphate 3′-3′-keto-2′- deoxynucleotide and 5′-aldehyde 
(Hutchinson, 1985; Dedon, 2008; Idldar et al., 1981) (Figure 1.1). In general, these products are unstable 
and degrade immediately to produce breaks with 5′- and 3′- phosphate.  Interestingly, 3′-PG as well as 
another oxidative product, thymine glycol (Tg), are chemically stable, which makes experiments involving 
these modifications more tractable (Evans et al., 2004).  
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Figure 1.1. Some of the major damaged termini of free radical-mediated DNA strand breaks. A. 
3′-phosphoglycolate (PG). B. 3′-phosphoglycoaldehyde. C. 3′-formyl phosphate. D. 3′-keto-2′-
deoxynucleotide. E. 5′-aldehyde. (Povirk, 2013) 
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1.3 Thymine Glycol 
Thymine is paired to adenine in the opposite strand in duplex DNA. Oxidative damage to thymine 
by IR, including that used in cancer therapy, and other chemical oxidizing agents results in 5,6-dihydroxy-
5,6-dihydrothymine, known as thymine glycol (Tg) which is the most common thymine oxidation product 
(Teoule et al., 1974; Frenkel et al., 1981) (Figure 1.2). Tg is also formed endogenously as result of aerobic 
metabolism. It is predicted that about 400 Tg moieties are generated per cell per day (Cathcart et al., 
1984; Saul and Ames, 1986).  Also, Tg causes distortion in the regular structure of DNA. The loss of 
aromatic property, and the presence of hydroxyl groups at the 5 and 6 sites of the ring makes Tg nonplanar 
(Evans and Dizdaroglu, 2004). Thymine glycol has been shown to be less mutagenic but a lethal lesion in 
vivo (Hayes et al., 1988).  Nevertheless, the presence of both Tg and 8-oxoguanine in the bistranded 
clustered damage site led to an increase in the mutagenic potential of 8-oxoguanine by Tg (Bellon et al., 
2009).  
While most of the IR-induced DSBs are efficiently being repaired by C-NHEJ, Tg may have a 
potential to render DSBs resistant to DSB repair and to block or slow their rejoining.  Therefore, it is very 
important to understand how the Tg is being processed in DSB repair pathways and particularly through 
the NHEJ.   
  
 
 
 
 
 
  
Figure 1.2. Oxidation of thymine to thymine glycol. (Pierre et al., 2007) 
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1.4 Base Excision Repair 
Base excision repair (BER) plays an important role in repairing oxidative DNA damage (McCullough 
et al, 1999, Rahmaniana et al., 2014). The first step in BER pathway is the recognition of the damaged base 
by a specific DNA glycosylase (Frosina et al., 1996).  The main DNA glycosylase in E. coli that is responsible 
for removing oxidatized pyrimidines such as thymine glycol is endonuclease III (Nth) (Eide et al., 1996) 
while the endonuclease III homologue in mammalian is NTH1 (Aspinwall et al., 1997).  The DNA glycosylate 
catalyzes the excision of the base by hydrolyzing the N-glycosidic bond leaving an Apurinic/Apyrimidinic 
(AP) site (Dianov et al., 2003). The developed AP site can be removed by AP endonucleases (APE1) in 
humans. Some glycosylases such as Nth and NTH1 also hold an intrinsic AP-lyase function and are able to 
hydrolyze the AP 3′-phosphodiester bond of the AP site generating 3′ α,β-unsaturated aldehyde and 5′-
phosphate products (Miral, 2005).  The phosphodiesterase activity of APE1 removes the sugar leaving a 
3′-hydroxyl . The repair proceeds with either short-patch repair or long-patch repair pathways (Slivar et 
al., 2011). The short-patch repair replaces only one nucleotide which is synthesized by DNA Polymerase β 
and the nick is ligated with XRCC1 and Ligase III proteins (Hegde et al., 2008).  Long-patch repair involves 
replacement of several nucleotides (2-13 nucleotides). RFC, Polymerase δ/ɛ, and proliferating cell nuclear 
antigen (PCNA) are enzymes that are responsible for adding the missing nucleotides. This will result in 5′ 
flap structure that can be removed by FEN1 while the nick is sealed by Ligase 1. 
1.5 Major DSB Repair Mechanisms 
1.5.1 Homologous Recombination (HRR) 
HRR requires a sister chromatid to act as a template for repair; therefore, HRR is only active in 
late S and G2 phases of the cell cycle and it is an error-free repair pathway (Helleday et al., 2007).  HRR is 
highly efficient in repairing DSBs due to replication fork collapse, IR and interstrand cross-links (Sung & 
Klein, 2006).  In HRR, the DSB is first detected by the MRN complex, and the DNA ends subjected to 5′3′ 
resection by CtIP, DNA2 and exonuclease 1 to generate a 3′-single strand DNA (ssDNA) overhang (Li and 
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Heyer, 2008).  Also, CtIP is known to be regulated by CDK and ATM (Chen et al, 2008; Li et al, 2000).  After 
that, replication protein A (RPA) binds to the 3′-ssDNA overhang to prevent premature strand invasion.  
Then, different proteins including Rad52, BRCA2 and the Rad51 paralogues (Rad51B, Rad51C, Rad51D, 
XRCC2 and XRCC3) are recruited to replace RPA with RAD51 (San et al., 2008).  This allows Rad51 to form 
a filament to invade a homologous sequence.  After that, DNA polymerase η is recruited to extend the 3′-
DNA end which leads to capturing a second DSB end to form Holliday junctions; these junctions are 
resolved in a process involving different proteins resulting in crossover or non-crossover products 
(Helleday et al., 2007; Li & Heyer, 2008).   
1.5.2 Classical Non-Homologous End Joining (NHEJ) 
NHEJ is the primary repair mechanism of DSBs (Figure 1.3), and it is the main repair mechanism 
in G0 and G1; even though it can function throughout the cell cycle (Rothkamm et al., 2003).  Also, NHEJ 
is essential mechanism in repairing DSBs due to V(D)J recombination (Jankovic et al., 2007).  There are 
three main steps in the NHEJ pathway including the detection of DSBs, removal of the non-ligatable end 
groups and religation of the processed DNA ends (Williamson et al., 2009).  In other words, repairing DSBs 
by NHEJ pathway involves nuclease, polymerase, and ligase activities (Lieber, 2010).  Several studies have 
shown the importance of some proteins in NHEJ pathway in human cells.  These proteins are Ku70/80 
heterodimer (Ku), DNA-dependent protein kinase catalytic subunit (DNA-PKcs), DNA ligase IV, XRCC4 and 
XLF (Cernunnos) (Lieber, 2010).  Once DBSs occur, the first step in NHEJ is the detection of the breaks, 
which is achieved by Ku in which Ku heterodimer is recruited to the end of the DNA damage (Weterings 
and Chen, 2008).  When Ku binds, it acts as a scaffold to facilitate the binding of other NHEJ proteins.  Also, 
Ku recruits DNA-PKcs, a member of the phosphoatidylinositol-3 kinase-like family of serine-threonine 
protein kinases (PIKKs), to form the DNA-PK complex which tethers the DNA ends together (Williamson et 
al., 2009).   Upon synapsis of the two DNA ends, DNA-PKcs phosphorylates itself in trans leading to its dis- 
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Figure 1.3. Nonhomologous end joining. The Ku 70/80 heterodimer binds to DNA DSB ends and recruits 
DNA-PKcs. This is followed by the recruitment of XLF:XRCC4:DNA ligase IV to the DNA ends which in turn 
leads to the synapsis of the two ends.  DNA-PK autophosphorylation causes a conformational change 
followed by its dissociation from the DNA ends.  This facilitates the access of downstream endonucleases 
proteins to process the DNA ends before gap filling by pol μ and λ and ligation that mediated by DNA 
ligase IV. Adapted from (Povirk and Valerie 2003). 
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sociation from the DNA ends, which facilitates the access of downstream proteins, to the ends of the DSB 
(Weterings, 2007).  After that, polymerases μ and λ are involved in gap filling (Mahaney et al., 2009), and 
the ends are ligated by the XRCC4-DNA ligase IV complex (X4L4), which is stimulated by an interaction 
between XLF and XRCC4. Also, there is a subpathway of NHEJ which may be necessary for a subpopulation 
of more-difficult-to repair DSBs, such as DSBs with heavily damaged termini, DSBs in heterochromatin, or 
DSB whose ends have become physically separated (reviewed in Valerie & Povirk, 2003).  This subpathway 
requires additional proteins (see below).  
1.5.3 The Choice of DSBs Repair Method 
Both DSB structure and chromatin complexities can affect the speed and choice of DSB repair 
pathway (Shibata et al., 2011).    When the DSBs occur in euchromatin DNA (EC-DNA) without DSB 
complexity, DSBs would be efficiently repaired with faster kinetics by NHEJ pathway independent to the 
cell cycle phase.  However, if DSBs occur in EC-DNA with high complexity, these DSBs would be repaired 
with slow kinetics in G1 and G2 phases by NHEJ, but NHEJ will stall in G2 phase allowing the DSBs to 
undergo resection to be repaired by HR.  However, in case of chromatin complexity, the DSBs would be 
repaired by NHEJ with slow kinetics in G1 phase.  Again, in G2 phase, NHEJ is inefficient and will stall 
allowing resection of the DSBs that would be repaired by HR.  However, the HR pathway can be switched 
to NHEJ for DSB repair in heterochromatin if the CtIP-dependent DSB end resection does not occur 
(Shibata et al., 2011).   
1.6 NHEJ Core Proteins 
1- The Ku70/80 heterodimer: 
The Ku heterodimer is composed of Ku70 (70 kDa) and Ku80 (86 kDa) subunits (Walker 2001), and 
it is responsible for detecting the DSB and tethering the DNA ends. Ku shows high binding affinity 
to ends of dsDNA without sequence specificity (Downs and Jackson, 2004). X-ray crystallography 
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indicates that the end-bound Ku occupies about 16-18 bp (Walker et al., 2001). The DNA binding 
domain is located at the C-terminus of Ku70 (Lees-Miller, 2003), while Ku80 has a conserved 
regions at the extreme C-terminus which is required for the interaction with DNA-PKcs. (Falck et 
al., 2005). In vitro studies have shown that Ku also interacts with other NHEJ proteins including 
XRCC4-DNA ligase IV (X4L4) complex, XLF, DNA pol μ and DNA pol λ (Mahaney et al., 2009). In vivo 
studies have shown that Ku is essential for the recruitment of DNA-PKcs, XRCC4 and XLF to DNA 
damage sites. 
2- DNA-PKcs: 
The molecular weight of DNA-PKcs is 469 kDa (4128 amino acids). It is a product of PRKDC gene, 
and it is a member of the phosphatidyl inositol 3-kinase like family of protein kinases (PIKKs) 
(Williamson et al., 2009). DNA-PKcs deficient cells have shown an increase in radiosensitivity as 
well as a defect in V(D)J recombination while the deficiency of DNA-PKcs in animals shows 
phenotype of severe combined immunodeficiency (SCID) (Meek et al., 2004). The DNA binding 
domain of DNA-PKcs is located within the amino terminal region (Gupta and Meek, 2005). DNA-
PKcs interacts with Ku through its C-terminus regions (Jin et al., 1997; Mordes et al., 2008). The 
binding affinity of DNA-PKcs to DNA increases in the presence of Ku (West et al., 1998). Once DNA-
PKcs is recruited to DNA ends, it displaces Ku inward by about 10 bp (Yoo and Dynan, 1999). Then, 
it starts to phosphorylate other proteins but it initially starts by phosphorylating itself in trans 
(Meek & Lees-Miller 2008). 
3- POL X Polymerases: 
The pol X family of DNA polymerases including pol μ, lambda λ and terminal deoxyonucleotidyl-
transferase (TdT) have been reported to be involved in NHEJ. They are essential in filling of DNA 
gaps that usually form after processing of IR-induced DNA damage (Povirk, 2006; Bertocci et al., 
2006; Lee et al., 2003).  These enzymes have a BRCT (BRCA1 C-terminal) domain which is essential 
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for their interactions with core NHEJ proteins forming a complex at the DNA ends (Ramsden, 
2011). BRCT-containing proteins have shown to be directly or indirectly involved in DNA damage 
response and repair (Bork et al., 1997). DNA pol μ and λ interact with Ku and X4L4 complex 
through their BRCT domains in order to be loaded at the DSBs. These two polymerases appear to 
function in most of the NHEJ process while TdT interacts with Ku and appears to be involved in 
V(D)J recombination only (Nick McElhinny and Ramsden, 2004). The quality of NHEJ repair 
depends on these polymerases even though cells deficient in pol μ and λ do not show an increase 
in radiosensitivity (Ramsden, 2011). 
4- XRCC4:DNA ligase IV and XLF:XRCC4:DNA ligase IV complex: 
The XRCC4 gene was isolated by complementation of radiosensitivity, V(D)J recombination 
deficiency and DSB repair deficiency of the Chinese Hamster ovary derivative XR-1 (Li et al., 1995). 
XRCC4 was found to be associated with DNA ligase IV, and in in vitro, the X4L4 complex is critical 
for ligation of broken DNA ends through the NHEJ mechanism (Critchlow et al., 1997). Also, XRCC4 
in cells was found to stabilize the DNA Ligase IV (Bryans et al., 1999). The ligation activity of X4L4 
is stimulated by an interaction with XLF; the most recently discovered core protein of NHEJ 
(Ahnesorg et al., 2006; Buck et al., 2006). XLF was identified initially as missing gene in a subset of 
severe combined immune deficiency (SCID) patients with characteristics of growth retardation, 
microcephaly, immunodeficiency, increased cellular radiosensitivity and a defective V(D)J 
recombination (Buck et al., 2006). Both proteins have no known enzymatic function, yet in 
mammalian cells, XRCC4-/- and XLF-/- genotype show increased sensitivity to ionizing radiation 
associated with severe defects in DSB repair (Giaccia et al., 1990; Zha et al., 2007).  
1.7 Other Proteins Involved in NHEJ 
5- Tyrosyl-DNA phosphodiesterases: 
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TDP1 is a highly conserved eukaryotic DNA repair enzyme that catalyzes the removal of covalent 
3′-DNA. The gene initially was isolated from Saccharomyces cerevisiae and was shown to repair 
stalled TOP1-DNA covalent complexes (Yang et al., 1996).  Also, yeast TDP1 was shown to regulate 
the accuracy of NHEJ (Bahmed et al., 2010). Human TDP1 works on both SSBs and DSBs and it is 
involved in the removal of tyrosyl-linked peptides and simple tyrosyl moieties from 3′ ends to 
produce a 3′-phosphate that can converted to 3′-hydroxyl by PNKP (Reviewed in Povirk, 2012). 
However, TDP1 is less efficient in removing other 3′ lesions such as 3′-PG and cleaved abasic sites. 
TDP1 is associated with the autosomal recessive neurodegenerative disease spinocerebellar 
ataxia with axonal neuropathy (SCAN1) (Takashima et al., 2002). TDP 2 is involved in the NHEJ 
mechanism through resolving the DSBs induced by TOP 2 (Gómez-Herreros et al., 2013). The 
mechanism by which TOP 2 induces DSBs is through promoting the relaxation and passage of 
duplex DNA (Deweese and Osheroff, 2009). TOP 2 is covalently attached to the two DNA ends 
through a phosphodiesterase bond to form tyrosyl DNA ends. TDP 2 has a strong activity toward 
the 5′-tyrosyl DNA ends and weak activity toward the 3′ ends (Gómez-Herreros et al., 2013) 
6- Polynucleotide kinase/phosphatase (PNKP) 
PNKP has 3’-DNA phosphatase and 5’-DNA kinase activities which removes 3’-phosphate and 
phosphorylates 5’ ends (Pheiffer and Zimmerman, 1982; Habraken and Verly, 1988) with no 
known function on other modified ends such as 3’-PG (Inamdar et al., 2002). PNKP has shown a 
role in NHEJ through an interaction with XRCC4 which promotes its recruitment to the DSB (Koch 
et al., 2004). PNKP also binds to XRCC1 to work on SSBs (Whitehouse et al., 2001). 
7- Artemis: 
Artemis possesses an intrinsic 5’3’ exonuclease activity and, in the presence of DNA-PKcs and 
ATP, it acquires endonuclease activity that opens DNA hairpins during V(D)J recombination 
process (Ma et al., 2002 and 2004) and removes and shortens long 3’ and 5’ overhangs at DSBs.  
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Deficiency of Artemis in humans results in radiation-sensitive severe combined immunodeficiency 
(RS-SCID) (Moshous et al., 2001).   Artemis doesn’t appear to be a major enzyme in DSB repair; 
nevertheless, it may be required for optimal rejoining of a subset of DNA damage events 
(Poinsignon et al., 2004; Wang et al., 2005). Artemis has been shown to trim 3’-PG-terminated 
overhangs to provide a 3’-hydroxyl ends (Povirk et al., 2007). Interestingly, the presence of a 
5’-phosphate terminus is essential for the 5’3’ exonucleolytic activity of Artemis while it is not 
required for the endonucleolytic trimming activity (Povirk et al., 2007) 
8- p53 binding protein 1 (53BP1) 
53BP1 was identified to bind to the central domain of human tumor suppressor protein p53 
(Iwabuchi et al., 1994) that is responsible for site-specific DNA binding. Interestingly, the binding 
of 53BP1 requires the p53 protein to be in its wild type conformation. The interaction between 
53BP1 and p53 appears to be through the BRCT domains of these proteins (Joo et al., 2002, 
Derbyshire et al., 2002). The BRCT motif of 53BP1 has a homology to BRCA1 and scRad9 (Callebaut 
and Mornon, 1997). 53BP1 has been shown to be involved in the DNA damage response pathway 
(Rappold et al., 2001) and it becomes hyperphosphorylated and immediately relocates to multiple 
nuclear foci in response to IR. In addition, 53BP1 has been shown to promote c-NHEJ in Ku 70/80 
and DNA ligase IV dependent manner (reviewed in Zimmermann and de Lange, 2014) mainly in 
class switch recombination (CSR), V(D) J recombination, telomere dysfunction, BRCA1-deficient 
cells, and centromeric heterochromatin. 
Other enzymes that may be involved in the end processing include MRE11, Werner’s syndrome 
protein (WRN), Aprataxin, PNK like factor (APLF), Apurinic/apyrimidnic lyases (APE1 and APE2), Metnase 
(Valarie & Povirk, 2003, Mahaney et al., 2009; Povirk, 2012). 
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1.8 Upregulation of NHEJ in Breast Cancer  
1.8.1 Breast Cancer 
Breast cancer in the United States is one of the most common cancers among women.  It is the 
second leading cause of cancer death in women, surpassed only by lung cancer (ACS, 2014).  Also, breast 
cancer is the number one cancer killer in women aged 20-59 years old (Ahmedin et al., 2010).  There is a 
chance of one out of eight women that will have an invasive breast cancer some time during their lives.  
Also, one out of 36 women expected to die in 2015 will do so as a result of breast cancer.  
Breast cancer treatment requires multiple approaches.  The recommended treatment for most 
patients with “invasive” breast cancer is surgical removal of primary tumor, systemic chemotherapy 
and/or hormonal therapy as well as radiotherapy (Buchholz, 2009).  Breast irradiation is indicated for most 
patients who undergo breast-conserving surgery (lumpectomy).  Also, radiation therapy is recommended 
after mastectomy for patients who are at high risk of developing recurrence (Shenkier et al., 2004).  The 
current treatment available for breast cancer has shown to be quite effective in suppressing the breast 
cancer growth and improving patients’ quality of life (Buchholz, 2009).  However, the risk of breast cancer 
recurrence is still not uncommon.  Recurrent breast cancer can occur months or years after the initial 
treatment.  Breast cancer recurrence can reappear as local recurrence at the original tumor site (invasive 
or noninvasive ipsilateral breast tumor recurrence), as regional recurrence in the axilla, chest muscle, 
internal mammary lymph nodes or supracavicular fossa lymph nodes, or as distant recurrence (metastasis) 
in which the tumor cells leave the breast tissue and spread to other sites including bone, lungs, brain and 
other organs (Millar et al., 2009; Clarke et al., 2005; Bruce et al., 2006).  The prognosis of recurrence and 
metastatic breast cancer is generally poor and associated with high resistance to further treatment and 
reduced survival rate (Dean-Colomb and Esteva, 2008; Gonzalez-Angulo et al., 2007; Jameel et al., 2004).  
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1.8.2 The Choice of DSBs Repair Mechanism in Breast Cancer 
Breast cancers can be divided into two types; the first type, known as sporadic breast cancer, 
develops after conception and accounts for 90-95% of breast cancer cases. The other type of breast 
cancers is familial breast cancer due to mutated genes inherited from one’s parents.  It accounts for 5-
10% of all breast cancers, and about 35 - 45% of familial breast cancer can be attributed to mutation in 
two different tumor suppressor genes known as BRCA1 and BRCA2 (Rosen et al., 2003; Miki et al., 1994; 
Wooster et al., 1995).  Nevertheless, mutations in either of BRCA1 or BRCA2 occur occasionally in sporadic 
breast cancer (Futreal et al, 1994; Lancaster et al, 1996).   In addition to the role of mutated BRCA1 and 2 
in predisposing individuals to breast cancer, these two proteins play an important role in protecting 
genome stability by responding to DNA damage.  Particularly, these genes have been shown to be involved 
in DSBs repair and are mainly critical for efficient HR but appear to play only a minor role in NHEJ, although 
BRCA1 may influence NHEJ fidelity (Gudmundsdottir and Ashworth, 2006; Nagaraju and Scully, 2007; H. 
Wang et al., 2001; Zhuang et al., 2006).  Many sporadic breast tumors show allelic loss (Johnson et al., 
2002) and/or reduced expression of BRCA1 and BRCA2 (Birgisoittir et al, 2006; Jaspers et al., 2009; 
Yshikawa et al., 1999; Wilson et al., 1999) suggesting that those tumors would be more dependent on 
NHEJ.  Conversely, breast tumor cells often show upregulation of receptors of the epidermal growth factor 
(EGFR) family (Johnson et al., 2006), which have been implicated in radioresistance (Contessa, Abell, 
Mikkelsen et al., 2006; Contessa, Abell, Valerie et al., 2006) and stimulation of NHEJ (Das et al., 2007).  
Therefore, targeting NHEJ may selectively increase radiosensitivity of many breast tumor cells. 
1.8.3 XRCC4-XLF Interaction as a Target for Radiosensitization 
Crystal structure studies of XRCC4 and XLF show structural similarity (Figure 1.4 and Figure 1.5) in 
which both proteins form homodimers and have similar N-terminal head domains and long α helical tails 
(Li et al., 2008; Andres et al., 2007; Junop et al., 2000). Mutagenesis studies of the head domains of XRCC4 
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and XLF (Figure 1.5)found residues E55, D58, M61 and F106 of XRCC4, and R64, L65 and L115 of XLF as 
critical to XRCC4-XLF interaction (Ropars et al., 2011; Malivert et al., 2010).  Based on the crystal structures 
of XRCC4 and XLF, and based on mutagenesis analysis, it has been suggested that these two proteins could 
form filaments of alternating XRCC4-XLF dimers which could twist a DSB and help to align the ends (Andres 
et al., 2007).  Regardless of the accuracy of the predicted filament formation between XRCC4 and XLF, the 
interaction between these proteins is essential for NHEJ.  Thus, this critical interaction should be 
susceptible to disruption by small peptides that bind this XLF-interacting region of XRCC4, and such 
disruption should severely suppress NHEJ. 
  
 
 
16 
 
 
 
  
Figure 1.4. Crystal structures of XRCC4 and XLF. Both XRCC4 and XLF have a head domain and long α helix 
(Andres et al., 2007)  
 
XRCC4 XLF 
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Figure 1.5. Filaments of alternating XRCC4-XLF dimers.  Proposed filaments that show the 
formation of alternating filaments between XLF (orange) and XRCC4 (blue).  The binding of 
XRCC4 to Ligase IV (yellow) is also indicated (Andres et al., 2007).  
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Figure 1.6. Interface of the XRCC41–157-XLF1–224 complex formed by the distal part of their N-terminal 
head domains. Residues involved in the interface between XRCC44 (cyan) and XLF (green) are shown in a 
stick representation.  Residues are labeled with “X” and “C” superscripts for X4 and Cernunnos (XLF), 
respectively. Dashed lines indicate inter- and intra-molecular hydrogen bonds and salt bridges between 
side-chain atoms proposed from Rosetta modeling. (Taken from Ropars et al., 2011) 
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1.9 XRCC4-XLF Interaction as a Good Druggable Target 
Many proteins produce their functions by interacting with other proteins. XRCC4-XLF interaction 
is one of those which occurs only in NHEJ and this mechanism is highly upregulated in most breast cancers. 
The nature of the interaction between XRCC4 and XLF that occurs in a distinct region facilitates inhibitor 
design (Hammel et al., 2011)(Figure 1.7) .  Also, the presence of a well characterized binding site with a 
hydrophobic Leu-lock motif makes this interface a good place to look by high-throughput screening for 
therapeutic inhibitors.  
Peptides have become an interesting class of inhibitors, which can explore large contact surfaces 
involved in protein-protein interactions. The advantages of peptides include their flexibility, the ability to 
manipulate the procedure of their development to produce highly specific and tight binders, their small 
size, and their low toxicity (Higueruelo et al., 2013). There are many techniques available to search for 
peptides as modulators of protein-protein interactions and mRNA display is one of the best technologies 
in this field. 
1.10 mRNA Display 
mRNA display is an in vitro selection technology that can be used to synthesize libraries of mRNA-
peptide fusions containing up to 10 trillion unique sequences (Roberts & Szostak, 1997). The main idea of 
this technology is the covalent attachment of the peptide chain to the 3′ end of its own mRNA template.  
The process starts when the mRNA first becomes covalently attached at its 3′ end to a puromycin 
containing short DNA linker via a psoralen photo-crosslink.  During an in vitro translation, when the 
ribosome reaches the crosslinked region and translation pauses, puromycin mimics the 3′ end of an 
incoming tRNA by entering the ribosome A-site and accepting the nascent peptide, forming the covalent 
bond between the mRNA and the peptide it encodes.  Using a library of mRNAs transcribed from a synthet- 
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   A. 
B. 
Figure 1.7. XRCC4-XLF interaction interface. A) Shows the interaction between XRCC4 (Red) and XLF (blue) 
through the head domain of these protein. B) Shows the hydrophobic pocket of XRCC4 where the XLF 
“Leucine” fits in. 
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ic DNA template, this process will create large collections of mRNA-peptide fusions.  The RNA portion of 
the mRNA-peptide fusions can be reverse-transcribed and PCR-amplified, which allows for the 
identification of the functional peptide by DNA sequencing.  Several rounds of selection and amplification 
can be carried out in order to allow for an enrichment of unique sequences with the required properties.  
1.11 Advantages of mRNA Display Technique 
1.11.1 Removal of non-specific binders: 
It is very important to remove nonspecific binders which are sometimes selected as a result of 
some experimental biases. This requires increase in the stringency during the selection, which is not 
tolerable for some techniques.  For example, the interaction of the peptides with the target occurs in the 
cell nuclei in the yeast two-hybrid technique (Huang et al., 2007), which prevents the increase in selection 
stringency. The other technique that cannot tolerate harsh selection condition is ribosome display (Hanes 
and Plückthun, 1997). While both mRNA display and ribosome display share some similarities such as 
using cell-free translation system and production of very high diversity library, they differ in the type of 
bond that links the mRNA and peptide. The mRNA and peptide are linked with stable covalent amide bond 
in mRNA display while they are linked with a less stable noncovalent bond in ribosome display. Therefore, 
very rigorous conditions cannot be used during the selection in ribosome display because the genotype is 
linked to the phenotype with a chemically fragile bond.  In contrast, the freedom of using arbitrary 
selection conditions makes mRNA display advantageous over other techniques. 
1.11.2 Development of Large Libraries: 
Some of the selection techniques that are used to look for target-binding partners are limited in 
the abundance of their libraries. For example, phage display, which is an in vivo technique produces a 
library of about 108 - 1010 (Hammers and Stanley, 2014). Yeast two-hybrid is a cell-based selection 
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produces a library with about 1 million variants (Huang et al., 2007).  However, mRNA display is a 
completely in vitro selection technique which can produce peptide libraries in the range of 1012 - 1014 
unique sequences (Roberts & Szostak, 1997). The development of large library size results in an increase 
in the binding affinity of the selected peptides as well as an improvement in the specificity.   
1.12 Applications of mRNA Display  
mRNA display has many applications.  For example, this method has been used to identify 
molecules that bound to TNF-α with a dissociation constant of 20 pM (Xu et al., 2002).  Also, this technique 
was used to select molecules that bind to phosphorylated IkBα with an affinity of 18 nM (Olson et al., 
2008).  Moreover, mRNA display was helpful in selecting Bcl-xL inhibitor with an IC50 of 0.9 µM 
(Matsumura et al., 2010).  In addition, an inhibitor with an IC50 of 2-5 nM has been identified by mRNA 
display to inhibit a protein-ligand interaction between VEGF and its receptor Flt-1 with 800 Å2 of buried 
interfacial surface area (Getmanova et al., 2006; Wiesmann et al., 1997).  Also, mRNA display has been 
used to develop two unnatural and one natural peptide inhibitors of thrombin with Kd in nanomolar range 
(Guillen Schilppe et al., 2012).  The unnatural peptide inhibitors have Kd of 4.5 and 20 nM while the natural 
one has a Kd of 1.5 nM.  Recently, Hartman’s group used mRNA display and discovered the first 
nonphosphate or phosphonate-containing peptide that binds a (BRCT)2 domain and blocks the protein-
protein interactions of the BRCA1 (BRCT)2 domain in cell lysates and disrupts HRR (White et al., 2015) 
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1.13 Specific Aims 
- To assess the Tg resistance to DSB repair by examining end joining of defined DSBs with a proximal Tg in 
a cell extract-based system and the role of XLF in facilitating their repair.  
- To develop peptide inhibitors of the XRCC4-XLF interaction in order to radiosensitize breast tumor cells. 
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2. METHODS 
 
2.1 Production of Wild Type XLF and XLF mutants (L115A and L1145D) Proteins 
2.1.1 Construction of XLF Mutants (L115A and L115D) 
For expression in Escherichia coli, we have a full-length XLF gene cloned into plasmid pQE80L with an N-
terminal 6× His tag (gift of Dr. David Chen, University of Texas Southeastern). The L115A and L115D 
mutants were generated using the QuickChange site-directed mutagenesis kit (Stratagene), and the 
following primers determined by the QuickChange Primer Design Program (Stratagene):  
5'-AAATTCCAATAGAAGGGGGCGCCAGAGAGCTCACTTCG-3' and 
5'-CGAAGTGAGCTCTCTGGCGCCCCCTTCTATTGGAATTT-3' for L115A and 
5'-AAATTCCAATAGAAGGGGTCGCCAGAGAGCTCACTTCG-3' and 
5'-CGAAGTGAGCTCTCTGGCGACCCCTTCTATTGGAATTT-3' for L115D.  
The mutated residues are highlighted in which the leucine (CTC) was mutated to either alanine (GCC) or 
to aspartic acid (GAC). Then, each mutant plasmid was transformed into E. coli. 5 µL pQE80L-XLFL115A and 
pQE80L-XLFL115D were transformed into E. coli competent (DH5 α) bacterial cells (Strategene) by heat 
shock.  The DNA and E. coli cells were mixed and placed on ice for 30 minutes, placed in a 42oC water bath 
for 45 seconds and placed on ice for 2 minutes.  Following 2 minutes on ice, 1000 µL of LB broth was added 
followed by 1 hour incubation with agitation at 37oC.  In order to grow a mix of colonies, following 
incubation, 10 µL, 100 µL, 200 µL of the transformation mix were spread on LB agar plates containing 100 
µg/ml ampicillin and incubated at 37oC overnight.  pQE80L contains an ampicillin resistance gene.  
Therefore, E. coli colonies that contain pQE80L should grow in the presence of ampicillin.  Individual 
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colonies that grew on agar plates were selected using a sterile toothpick and each colony was added to 5 
mL of LB medium containing 100 µg/ml ampicillin and incubated at 37oC overnight with gentle agitation.  
Plasmid DNA from individual colonies were isolated using mini-prep plasmid DNA isolation kit from 
QIAGEN.  Confirmation that the plasmid DNA, isolated from the colonies, contained XLFL115A or XLFL115D 
and pQE80L was achieved by digesting the purified colonies with BamHI and HindIII restriction enzymes 
and electrophoresis using a 1% agarose gel (Figure 2.1).  Furthermore, confirmation was achieved by DNA 
sequencing (Figure 2.2).     
Figure 2.1 The full length XLFL115D cut from pQE80L vector.  Then, the XLFL115D was cut out from the pQE80L 
vector with BamHI and HindIII restriction enzymes.   Two bands were formed; the upper band is around 
4700 bp indicating the pQE80L vector and the lower band is around 900 bp indicating the XLFL115D DNA.  
The results show that the samples in lanes 1-9 and 11-12 have an insert of the expected size. 
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Figure 2.2 XLFL115D sequence. Red circle indicates the site of the mutation inserted in which the Leucine 
(CAC) was mutated to Aspartic acid (GAC).  
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2.1.2 Production of Wild-Type XLF, XLFL115A and XLFL115D Proteins 
Wild type and mutant plasmids were expressed in E. coli BL21 (DE3) competent cells and induced 
using IPTG.  First, single colonies of the plasmids harboring wild-type, XLFL115A or XLFL115D were grown 
overnight at 37oC with agitation in 5 mL LB medium containing 100 µg/ml ampicillin.  Then, 1 ml of the 
overnight cultures was transferred into four each of 2 L flasks containing 500 mL LB medium (each 500 mL 
culture contains 5 gm tryptone, 5 gm NaCl, 2.5 gm yeast and 500 µL of 100 µg/ml ampicillin).  The four 
cultures were inoculated at 37oC with agitation and at an optical density (600 nm) of 0.5, IPTG was added 
to 1 mM for induction. Four hours later, the cells were centrifuged at 4000 rpm and 4°C for 30 minutes, 
and the dry pellets were stored at – 20oC until use. 
2.1.3 Ni-NTA Purification 
Cell pellets were left to thaw in ice and the pellet in each bottle was resuspended in 5 ml of freshly 
prepared Basic Buffer N (50 nM phosphate pH 8, 10% glycerol, 5 mM fresh 2-mercaptoethanol (BME), 20 
mM imidazole and 0.5 M NaCl) and 150 µL His-compatible protease inhibitor (Merck, EMD).  After that, 
the cells were transferred into a 50 mL centrifuge tube and sonicated 4X 45 seconds on 30% power (Sonic 
Dismembrator model 100 from Fisher Scientific).  The lysed cells were diluted with 20 mL Basic Buffer N 
and centrifuged for 15 minutes at 15000 rpm at 4°C.  Then, the supernatants were transferred into a 50 
mL Falcon tube and mixed with 4 mL Ni-NTA resin (QIAGEN) and gently stirred for 1 hour at 4°C.   After 
that, the mixture was transferred into a-20 mL Econo-Pac Chromatography Columns (Bio-Rad) the flow 
through was collected by gravity and the resin washed with 20 mL of Basic Buffer N and collected by 
gravity as well.  The protein was eluted by gravity 6 times and each time was with 1 mL of Ni-NTA elution 
buffer (50 mM NaH2PO4, 300 mM NaCl and 250 mM imidazole; pH 8).   All six fractions were analyzed by 
SDS-PAGE electrophoresis (Figure 2.3), and peak fractions were dialyzed against 20 mM Tris–HCl pH 8.0 
overnight. XLF wild-type and mutants proteins were filtered (0.22 μm), loaded on a MonoQ FPLC column 
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(Pharmacia) and eluted with a gradient of 0–0.8 M NaCl in 20 mM Tris–HCl pH 8.0 over 20 minutes. 
Fractions were collected and analyzed by SDS–PAGE (Figure 2.4). XLF-containing fractions eluted at ∼0.75 
M NaCl and were stored at −20°C in the elution buffer plus 50% glycerol. Final concentration of the protein 
was determined using Pierce BCA assay with BSA as standard. 
  
Figure 2.3 Protein composition of A) WT XLF and B) XLFL115D after Ni-NTA purification as determined by 
SDS-PAGE.  A) and B) 10% polyacrylamide gradient gel stained with coomassie blue.  Lane 1: 30 µL of 
lysate was loaded (out of 5 mL). Lane 2: 30 µL of flow through was loaded (out of 5 mL).  Lane 3: 30 µL of 
washes (out of 20 mL).  Lane 4-9: 30 µL of different protein elutions (each elution was 1 mL). The results 
show that the samples in lanes 4-9 have the XLF protein on the expected size. 
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Figure 2.4 Protein composition after FPLC purification as determined by SDS-PAGE.  Different fractions 
of each protein were collectd and run on 10% polyacrylamide gradient gel stained with coomassie blue. 
(A) WT XLF and (B) XLFL115A. Lane 1,3,5,7: 10 µL of different fractions (each was 1 mL) was loaded. Lane 
2,4,6,8,9: 30 µL of different fractions (each was 1 mL) was loaded. (C) XLFL115D. Lane 1: 30 µL of WT XLF 
was loaded. Lane 2: 30 µL of XLFL115D protein before FPLC was loaded. Lane 3-9: 30 µL of different fractions 
(each was 1 mL) was loaded. 
 
A. 
B. 
C. 
37 kD 
25 kD 
37 kD 
25 kD 
37 kD 
25 kD 
 
 
30 
 
2.2 Substrate 
Plasmid pUC19 (34 μg) was cut with BstAPI and KasI and the larger 2.6-kb fragment was agarose 
gel-purified and electroeluted.  The 25-mer ATGCGGATCGCGTTGTCT (50 pmoles), either unmodified or 
with Tg as the 3′-terminal base, was 5′-32P end-labeled with T4 polynucleotide kinase (PNK) in a volume of 
10 μl.  After inactivation for 3 min at 90°C, it was annealed to 50 pmole of pAGACAACGCGATCCGCATATG 
by heating to 80°C followed by slow cooling to 10°C, resulting in a duplex with a 3-base -ATG 3′ overhang 
that is complementary to the -CAT 3′ overhang of the BstAPI site (Figure 2.5).  Thus, 8 pmole of the duplex 
was ligated to 2 pmole of the BstAPI/KasI fragment by treatment with 12,000 units (4 µl) units T7 DNA 
ligase for 2 hr at 25°C in 130 μl of the buffer provided by the vendor (66 mM Tris-HCl, 10 mM MgCl2, 1 
mM ATP, 1 mM dithiothreitol, 7.5% polyethylene glycol, pH 7.6).  Under these conditions, blunt-end 
ligation by T7 ligase is negligible (Doherty et al., 1996), so that the dominant product was a double-length 
plasmid joined tail-to-tail at the KasI sites, with the labeled duplex linked to each end (Figure 1A).  This 
product was cut with SmaI and the final 2.1-kb substrate with one modified and one unmodified blunt 
end was gel-purified.   Substrates with Tg as the second base (terminal sequence -TTGC-Tg-C), third base 
(-TTG-Tg-CT) or fifth base (-T-Tg-GTCT) from the 3′ end, were similarly constructed. 
 
 
 
 
 
Figure 2.5.  Tg-containing DSB substrates.   Construction 
of modified substrates from short, end-labeled (*) Tg-
containing duplexes and a fragment of pUC19.  .   
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2.3 End Joining Reactions   
Reactions in extracts contained 50 mM triethanolammonium acetate pH 7.5, 1 mM ATP, 1 mM 
dithiothreitol, 50 μg/ml BSA, 1.3 mM magnesium acetate and dNTPs (or ddNTPs) at 100 μM each. 
Typically, a 16-μl reaction contained 10 μl of extract, resulting in a final concentration of 8 mg/ml protein, 
66 mM potassium acetate and 16% glycerol, and an effective Mg++ concentration of 1 mM (taking into 
account ∼0.3 mM EDTA from the extract). Buffer components were first mixed with cell extract at 22°C.   
Recombinant proteins (XLF and/or Artemis) were then added, followed immediately by the substrate (20 
ng).  The reaction was again mixed by pipetting, and placed in a 37°C water bath, usually for 6 h.  Samples 
were then deproteinized as described (Doherty et al., 1996), ethanol-precipitated in the presence of 1 μl 
GlycoBlue coprecipitant (Invitrogen), cut with NdeI and PstI (20 units each) for 3 hr in 40 μl of NEB 
CutSmart buffer (50mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 100 μg/ml 
BSA, pH 7.9) and analyzed on 20% polyacrylamide DNA sequencing gels.  Storage phosphor screens were 
exposed to frozen polyacrylamide gels for 40 hr, and images were analyzed with ImageQuant 5.1 software.  
For some experiments, samples were treated with E. coli endonuclease III (EndoIII) to cleave Tg-containing 
products.  For treatment prior to restriction cleavage, half of each deproteinized, precipitated sample was 
treated with 20 units EndoIII for 2 hr at 37°C in 20 μl of the buffer provided by the vendor (20 mM Tris-
HCl, 1 mM EDTA, 1 mM dithiothreitol, pH 8), followed by EndoIII inactivation for 20 min at 65°C and 
addition of NdeI, PstI and CutSmart buffer.  In other experiments, after NdeI/PstI cleavage, sodium acetate 
was added to 0.3 M along with a 44-base oligomer (100 nM) complementary to the expected Tg-
containing strand of a blunt-end ligation product.  The sample was denatured at 90°C and then annealed 
by slow cooling to 10°C.  Samples were then ethanol-precipitated and treated with EndoIII as above, and 
again precipitated prior to denaturing gel electrophoresis.   
2.4 Polyacrylamide Gel Electrophoresis 
Polyacrylamide gels (20x30x0.08cm) for electrophoretic separation contained 20% acrylamide: 
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bisacrylamide in a ratio of 20:1 with urea added to a final concentration of 8.3 M for electrophoretic 
separations. After the urea dissolved, the mixture was cooled to room temperature before adding 0.075% 
(w/v) ammonium persulfate and 0.03% (v/v) TEMED (N’, N’,N’,N’-tetramethylethylene diamine). The gel 
was allowed to polymerize for 1 hour. Samples then loaded into the wells of the gel and electrophoresed 
at constant power of 42 watts for 3-4 hours in 1X TEB running buffer. 
2.5 Statistics 
Error bars represent standard error of mean (SEM) for at least three independent experiments. 
Unpaired two-tailed t-tests were performed and the data were reported as significant for P values <0.05. 
2.5 mRNA Display and In Vitro Selection 
2.5.1 DNA library Synthesis 
Five different DNA libraries have been synthesized (by Dr. Hartman) and used in the selection 
process.  Briefly, each library encodes a fixed cysteine at the N-terminus and another cysteine after 2, 4, 
6, 8, or 10 random amino acids in order to produce different cyclic sizes of peptides.  The DNA sequence 
of the random library is: 
TAATACGACTCACTATAGGGTTAACTTTACTAAGGAGGACAGCTAAATGTGCNNSNNSNNSNNSNNSNNSNNSNN
SNNSNNSNNSNNSNNSGGTAGCGGCTCCTTAGGCCACCATCACCATCACCACCGGCTATAGGTAGCTAG 
The detailed sequence composition of each library is as follows:  
1- TAATACGACTCACTATA: T7 promoter, followed by GGG with the first “G” as the transcription start.  
2- TTAACTTTAG: Epsilon enhancer.  
3- TAAGGAGG: Shine-Dalgarno sequence, also known as the ribosome binding site.  
4- ACAGCTAA: the Spacer between ribosome binding site and the start codon, with “AA” at end. 
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5- ATGTGCNNS’sTGCNNS’s: translation start codon for methionine (ATG) and the codon for the fixed 
cysteine (TGC), followed by a mix of random NNS codons and another fixed cysteine at the site indicated 
above. We used the NNS (S=C/G) codon in the random region to decrease the prevalence of stop codons 
as compared to NNN (A=A/T/G/C). The translated peptides have the sequence of MCX2CX10GSGSLGHis6, 
MCX4CX8GSGSLGHis6, MCX6CX6GSGSLGHis6, MCX8CX4GSGSLGHis6, or MCX10CX2GSGSLGHis6, where X 
can be one of the natural amino acids.  
6- GGCTCCGGTAGCTTAGGC: codons for GlySerGlySer- LeuGly, the flexible linker with two out-of-frame 
stop codons.  
7- CACCATCACCATCAC: codons for His5 tag. The sixth His of His6 tag is in the following sequence.  
8- CACCGGCTAT: hybridization region for the Psoralen crosslinker (XL-PSO oligonucleotide, see below). 
The CAC encodes the sixth His of the intact His6 tag.  
9- AGGTAGCTAG: 3’ -UTR to allow those non-crosslinked peptides to release at the in-frame TAG stop 
codons.  
2.5.2 PCR Amplification of Library DNA 
The DNA libraries were synthesized in reverse orientation.  For example, CTAGCTACCTATAGCCGG-
TGGTGATGGTGATGGTGGCCTAAGGAGCCGCTACCSNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSNNSN
NGCACATTTAGCTGTCCTCCTTAGTAAAGTTAACCCTATAGTGAGTCGTATTA.  Then, the DNA libraries were 
amplified by PCR using the following primers 5′-TAATACGACTCACTATAGGGTTAACTTTACTAAGGAGGACA-
G-3′ and the 5′-CTAGCTACCTATAGCCGGTGGTGATGGTGATGGTGGCCTAAGGAGCCGCTACC-3′.  Each PCR 
reaction contained 12 nM of DNA library, 0.5 µM of each primer, 1X ThermoPol buffer, 100 µM of dNTP’s 
and 5 U of Taq polymerase.  The PCR reaction started by an initial heating of 94°C for 2 minutes followed 
by 18 cycles of 94°C for 15 seconds, 60°C for 30 seconds, and 72°C for 45 seconds followed by 72°C for 5 
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minutes.  PCR product amplified was mixed with sample buffer and resolved on a 2% agarose gel 
containing ethidium bromide for visualization using UV (Figure 2.6).  PCR product was cut from the gel 
and gel purified by QIAquick Gel Extraction Kit from QIAGEN. 
  
Figure 2.6 DNA library on 2% agarose gel.  Lane 1: CX2CX4 DNA library. Lane 2: CX4CX8 DNA library. Lane 
3: CX6CX6 DNA library. Lane 4: CX8CX4 DNA library. Lane 5: CX10CX2 DNA library. Lane 6: no template.  
The upper bands were cut and gel purified. 
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2.5.3 StrataClone Cloning and Sequencing 
The PCR product was ligated to StrataClone vector (Stratagene).  The ligation product was 
transformed into StrataClone SoloPack competent cells following the StrataClone PCR Cloning Kit from 
Stratagene.  After that, the transformation product was plated onto LB plates containing 20 mg/ml 
kanamycin and the plates were incubated overnight at 37°C.  Then, 96 single colonies were selected and 
sent for sequencing to ensure that the libraries were synthesized as designed (Figure 2.7).  
Figure 2.7: DNA libraries sequence.  Each library was PCR-amplified and sample clones were sequenced.  
The predicted amino acid sequence from each clone is shown. The sequences of the libraries were 
analyzed by using Bio-Edit software 
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2.5.4 Transcription and Purification of mRNA 
 Each library was transcribed by setting up a 1 ml transcription reaction that contains 0.1 µM DNA 
library, 0.6 µM T7 primer, 40 mM/0.1% Tris/Triton solution, 2.5 mM spermidine, 25 mM MgCl2, 10 mM 
DTT, 5 mM CTP, 5 mM UTP, 5 mM ATP, 9 mM GTP, 0.2 U/µl RNase inhibitor, 1 U/µl inorganic 
pyrophosphatase and 1 U/µl T7 RNA polymerase (MA & Hartman, 2012).  Then, the reaction was 
incubated overnight at 37°C in an incubator chamber.  After that, the transcription reaction was removed 
from the incubator and 50 µL of Turbo DNase (Invitrogen) was added and the reaction was incubated for 
15 minutes at 37°C.  After incubation, 7.5 M urea was added and mixed well and the reaction was loaded 
on Urea PAGE by setting up a large 65 SequaGel (20 cm X 20 cm) on an Owl P10DS Dual Gel System. The 
gel was pre-run for 20–30 min by using constant power at 25 W supplied by EC Apparatus electrophoresis 
power supply EC 600.  Then, the urea was flushed out from well and the sample was loaded.  The gel was 
run at constant power of 25 W for 60-90 minutes until the bromophenol blue reaches the bottom of the 
gel.  After that, the gel was transferred from the glass plates to Saran wrap on both sides and the mRNA 
band was visualized by UV shadowing and the band cut out with a fresh razor blade. 
After that, the mRNA was eluted by using the Whatman Elutrap electroelution System. First, the 
gel slice was put into the chamber, and mashed into small pieces and the chamber filled with 0.5X TBE 
buffer until the gel is covered.  The electroelution was run for 2 h at 300 V on a Bio-Rad PowerPac basic 
power supply.  At the end of running, the electrodes switched and run backwards for 1 min at 300 V.  
Then, the solution between membranes was collected and ethanol precipitated with 0.1 volume of 3 M 
KOAc and 3 volumes of 100% ethanol.  The sample was mixed well and chilled at −20°C for 30 minutes.  
After that, the sample was centrifuged at 16,000 Xg for 20 minutes at 4°C.  The supernatant was discarded 
and the pellet washed with 500 µL of 70% ethanol and centrifuged again at 16,000 xg for 1 min.  The 
supernatant was discarded and the pellet air-dried for 5–10 min at room temperature.  The mRNA was 
dissolved in ddH2O and an absorbance at 260 nm was measured on a spectrophotometer.  The 
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concentration was calculated by using the online software Oligonucleotide Properties Calculator 
(http://www.unc.edu/~cail/biotool/oligo/index.htmL).  Then, the mRNA was stored at -20°C. 
2.5.5 Psoralen Photo-Crosslinking 
The five mRNA libraries were mixed together with a final concentration of 2 µM in order to be 
photo-crosslinked with an XL-PSO oligonucleotide.  The sequence of the XL-PSO oligonucleotide is 5′-
PsoC6-(UAGCCGGUG)2′-OMe-15xA-2xSpacer9-ACC-Puro-3′. Spacer9 is triethyleneglycol (TEG) 
phosphoramidites and it is used to tether 5′-dCdC-puromycin to the 3′-end.  The Psoralen photo-
crosslinking reaction contains 20 mM HEPES-KOH, pH 7.6, 7.5 µM XL oligo, 100 mM KCl, 1 mM spermidine, 
1 mM EDTA and the mixture of the mRNA libraries.  The reaction was mixed well and transferred into PCR 
tubes with 100 µl in each tube.  The PCR tubes were placed in a PCR machine, heated to 70°C for 5 min, 
then cooled to 25°C over 5 min (0.1°C/s).  After this, each sample was transferred to a crosslink plate, 100 
µL per well.  A 365 nm UV lamp was used to irradiate the plate for 20 minutes at 4°C.  The samples were 
collected in 1.5 ml eppendorf tube and ethanol precipitated as previously described.  The pellet was 
resuspended in the required volume.   
2.5.6 In Vitro Translation 
A 5-mL translation reaction was prepared, which contained 8 mM putrescine, 1mM spermidine, 
5 mM potassium phosphate, 95 mM potassium chloride, 5 mM ammonium chloride, 5 mM magnesium 
acetate, 0.5 mM calcium chloride, 1mM dithiothreitol, 1 µg/ml inorganic pyrophosphatase, 4 µg/ml 
creatine kinase, 1.1 µg/mL nucleotide diphosphate kinase, 30 µM (6R,S)-5,10-formyl-5,6,7,8-
tetrahydrofolic acid, 93 µg/mL myokinase, 10 mM creatine phosphate, 2 mM ATP, 2mM GTP, 2.4 mg/ml 
E. coli total tRNA, 0.2 µM MTF, 1.0 µM IF1, 0.3 µM IF2, 0.7 µM IF3, 3.2 µM EF-Tu, 0.6 µM EF-Ts, 0.5 µM 
EF-G, 0.3 µM RF1, 0.4 µM RF3, 0.1 µM RRF and 0.5 µM ribosomes. In addition, the reaction contained 18 
natural amino acids (200 µM each), 10 µM cysteine, 10 µM methionine and 20 aminoacyl tRNA 
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synthetases (0.1 µM MetRS, 0.3 µM LeuRS, 0.6 µM GluRS, 0.2 µM ProRS, 1.0 µM GlnRS, 1.0 µM HisRS, 
0.25 µM PheRS A294G, 1.5 µM TrpRS, 0.2 µM SerRS, 0.2 µM IleRS, 0.4 µM ThrRS, 0.6 µM AsnRS, 0.6 µM 
AspRS, 0.5 µM TyrRS, 0.5 µM LysRS, 0.4 µM ArgRS, 0.2 µM ValRS, 0.2 µM AlaRS, 0.5 µM CysRS, and 0.06 
µM GlyRS).  0.3 µM of 35S-Met is added to isotopically label the peptides.  The translation mix was 
incubated for 15 minutes at 37°C.  Then, the 2 µM photo-crosslinked mRNA was added to the translation 
mix and incubated for 1 hour at 37°C.  After that, the translation reaction was quenched with 550 mM KCl 
and 50 mM MgCl2 followed by an incubation for 90 minutes at 37°C.  Then, the translation reaction was 
chilled overnight at -80°C. 
2.5.7 Oligo(dT) Purification and Cyclization 
The goal of oligo(dT) purification and cyclization is to remove all non photo-crosslinked mRNA-
peptide fusions and to produce cyclic peptides at the same time (Figure 2.8).  The translation reaction was 
thawed and vortexed and 5 µL removed for scintillation counting to determine the total radioactivity of 
35S-Met added to the translation reaction.  Then, 100 mg Oligo(dT)-cellulose Type 7 powder (GE 
Healthcare) was added into each of five 20 mL Bio-Rad Econo-Pac columns (BioRad) and rinsed once with 
5 ml ddH2O to swell cellulose and twice with oligo(dT) binding buffer (20 mM Tris–HCl, pH 7.8, 10 mM 
EDTA, 1 M NaCl, 0.2% Triton X-100, and 0.5 mM fresh TCEP).  Then, each one ml of the translation reaction 
was added to one column and the reaction was brought up to 4 mL with the binding buffer.  The columns 
were placed on a rocking platform shaker in 4°C cold room and shaken for 30 min.  After that, the flow-
through was removed and the beads was rinsed twice with the oligo(dT) binding buffer.  Then, 4 mL of 
cyclization buffer (20 mM Tris–HCl, pH 7.8, 0.66 M NaCl, 3 mM α,α -dibromo- m -xylene (Sigma-
Aldrich/Fluka), 33% acetonitrile (v/v), 0.5 mM fresh TCEP) was added to each reaction and rocked for 30 
minutes at room temperature.  Then, the flow-through was removed and each column was washed twice 
with 4.5 mL olido(dT) wash buffer (20 mM Tris–HCl, pH 7.8, 0.3 M NaCl, 0.1% Triton X-100); first wash was 
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with 5 mM fresh BME and the other wash was with 0.5 mM fresh TCEP.  Then, the columns were eluted 8 
times with ddH2O and filtered to remove residual Oligo(dT)-cellulose in the fusion solution.  One µL of 
each eluent was counted in a scintillation counter and the fractions with significant radioactivity were 
combined and ethanol precipitated using 0.3 volume of 3 M KOAc, pH 5.2, 0.002 volume of glycogen 
(5mg/mL) (Applied Biosystems), and 3 volume of 100% ethanol.  Then, the pmole amount of the mRNA-
peptide fusion was calculated based on the scintillation counts and the pellet re-dissolved in ddH2O so 
that the final concentration of the fusion is 100 nM (0.1 pmole/µL). 
2.5.8 Reverse Transcription  
The goal of reverse transcription (RT) is to convert the single-stranded mRNA portions of the 
fusions to heteroduplex of RNA/DNA in order to eliminate any unwanted RNA secondary structures and 
render the nucleic acid portion of the fusion more stable.  The RT reaction was carried out following the 
Superscript III First Strand Synthesis Kit (Invitrogen).  In a microcentrifuge tube, the 100 nM mRNA-peptide 
fusions were added to 0.5 mM dNTPs and 0.5 µM RT-primer TTTTTTTTTTTTTTTGTGATGGTGATGGTGGCCT-
AAGC. The tube was incubated for 5 minutes at 65 °C in a heating block. After five minutes, the tube was 
immediately placed on ice and incubated for at least 1 minute.  Then, the following reagents were added 
in a final concentration of 5 mM MgCl2 , 1 mM DTT, 2 U/ µL RNaseOUT (Invitrogen), 5 U/ µL Superscript III 
(Invitrogen).  The RT reaction was incubated for 15 minutes at 55°C for elongation, then 15 minutes at 
70°C to inactivate the Superscript III.  At the end of the RT reaction, 0.5 µL of each RT reaction was counted 
in a scintillation counter in order to calculate how much of mRNA-peptide fusions were recovered.   
2.5.9 Ni-NTA Purification 
Ni-NTA purification was performed in order to remove any truncated peptide fusions (Figure 2.9).  
The following buffers were prepared for Ni-NTA purification under denaturing condition: 
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Denaturing Binding buffer, pH 8 Wash buffer, pH 8  Elution buffer, pH 8  
   100 mM NaH2PO4 
   10 mM Tris HCl 
   6 M guanidinium HCl 
   0.2% Triton X-100 
   5 mM BME (fresh) 
   100 mM NaH2PO4 
   300mM NaCl 
   0.2% Triton X-100 
   5 mM BME (fresh) 
   50 mM NaH2PO4 
   300mM NaCl 
   250mM imidazole 
   0.2% Triton X-100 
   5 mM BME (fresh) 
First, 100 µl of Ni-NTA agarose was added into spin filter tube.  Then, the RT reaction was diluted 
5 fold with the Ni-NTA denaturing binding buffer and transferred into filter tube.   The peptide fusion was 
bound to the Ni-NTA for one hour at 4˚C in a tumbler in a cold room.  After that, the flow through was 
removed by centrifuging at 5900 rpm for 1 minute.  The resin was washed 3 times with Ni-NTA wash buffer 
and centrifuged at each time.  Then, the peptide fusion was eluted 6 times with portions of 50 µL Ni-NTA 
elution buffer and 0.5 µL of each eluent was counted in a scintillation counter to measure how much of 
mRNA-peptide fusions recovered.  All eluents with high counts were combined and dialyzed against 1 L 
pre-cooled selection buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 4 mM MgCl2, 0.25% Triton X-100, 0.1 
mg/ml BSA).  The overnight-dialyzed peptide fusions were collected and 1 µL was counted in a scintillation 
counter. 
2.5.10 In Vitro Selection 
The selection process started by an overnight incubation of two proteins with Pierce Magnetic 
Glutathione beads (Thermo Fisher Scientific).  The first sample contains GST protein only for negative 
selection (pre-clearing) (Figure 2.10) and the second sample contains GST-XRCC4157 fusion for selection.  
50 µL of Pierce Magnetic Glutathione beads per 1 mL translation reaction was transferred into two 1.5 mL 
eppendorf tubes and washed three times with 400 µL GST beads wash buffer (125 mM Tris–HCl, pH 8.0, 
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150 mM NaCl); each time the magnetic beads were mixed gently and the supernatant was removed by 
using Magnetic separation stand (Invitrogen).  130 µg of each protein was mixed with 400 µL GST beads 
wash buffer and transferred to the tubes with magnetic beads and incubated at 4°C for overnight with 
rotation on a tube rotator.  In the next day, the magnetic beads with GST protein were pelleted briefly 
and the supernatant was removed using the magnetic stand.   The beads were washed twice with 400 µL 
GST beads wash buffer and once with 400 µL selection buffer.  Then, the dialyzed mRNA-peptide fusions 
from the previous step were added to the tube and a final concentration of 0.1 mg/mL BSA was added.  
The tube was incubated at 4°C for 2 hours with rotation.  After that, the supernatant was collected and 
the beads washed three times with 200 µL selection buffer. The beads from this step and 10 µL from the 
supernatant and washes were counted in a scintillation counter. Then, the remainder of the supernatant 
and the three washes were transferred to the other tube that contained the GST- XRCC4157 fusion.  The 
tube was incubated at 4°C for 2 hours with rotation. Then, the supernatant was removed and the beads 
were washed three times with 400 µL of the selection buffer. Then, the beads were suspended in 100 µL 
of the selection buffer and 5 µL was counted in a scintillation counter. After that, the mRNA-peptide 
fusions that attached to the GST-XRCC4157 were amplified by PCR directly from the beads as described 
below. 
2.5.11 PCR Amplification of Selected Fusions 
The PCR reaction was carried out directly from the beads.  First, a test of 100 µL PCR reaction was 
done with 5 µL of the suspended beads in order to find the optimum conditions for PCR.  The PCR reaction 
was performed as previously described with the following primers 5′-TAATACGACTCACTATAGGGTTAACT- 
TTACTAAGGAGGACAGCTAAATG-3′ and the 5′-CTAGCTACCTATAGCCGGTGGTGATGGTGATGGTGGCCTAAG-
GAGCCGCTACC-3′.  Starting in cycle 14, 5 µL was taken out of the PCR tube after the elongation step (step 
4, at 72°C).  The PCR machine was paused at 44 seconds of this step and 5 µL was taken from the PCR 
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reaction. This was done for even numbered PCR cycles 14-32.  The PCR product was checked on 2% 
agarose gel and the intensity of DNA bands was analyzed to find out the optimum conditions of the PCR.  
Then, large-scale PCR was set up using multiple PCR tubes and all suspended beads were used to amplify 
the selected fusions.   After PCR, the reaction mixtures were combined and an equal volume 
phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma-Aldrich) was added.  The sample was vortexed and 
centrifuged at 4000 rpm for 2 minutes in a cold room.  The upper layer was transferred to a new tube and 
an equal volume of CHCl3 was added to the tube and spun down again.  The aqueous layer was transferred 
to new tube and ethanol precipitated as previously described.  The resulting precipitate was dissolved 
into a final volume of 100 µL ddH20, and passed over a NAP-5 column (GE Healthcare) to de-salt.  The final 
volume from NAP-5 was 500 µL.  This was the template for the next round of selection. 
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Figure 2.8 In vitro transcription, photo cross-linking and in vitro translation 
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1  Oligo dT Purification 
2  Cyclization with dibromoxylene 
3  Reverse Transcription 
4  Ni NTA Purification 
Figure 2.9 mRNA-peptide fusions purification steps. 
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mRNA - peptide Fusions 
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Wanted mRNA-peptide fusions 
Unwanted mRNA-peptide fusions 
Figure 2.10. Pre-clearing (negative selection) with GST protein only immobilized on magnetic beads 
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2.6 Peptide Synthesis 
2.6.1 Solid Phase Peptide Synthesis 
Standard Fmoc-based solid phase peptide synthesis was used to synthesize the peptides on a 
Liberty Automated Microwave Peptide Synthesizer (CEM). The peptides were made on a Fmoc-Rink amide 
MBHA Resin (0.65 mmol/gm). After each coupling step a capping step was performed using 20% acetic 
anhydride (Fisher Certified ACS), but no capping was performed on the final N-terminal amino acid to 
leave the amine free for labelling. The formation of the peptides were confirmed by MALDI-TOF.  
2.6.2 Labeling with 5(6)-Carboxyfluorescein 
The peptides were labeled using 600 µmole 5(6)-carboxyfluorescein (FAM) (Sigma-Aldrich), 600 
µmol DCC, 600 µmole HOBt and 30 µmol peptide resin in DMF. The labeling was confirmed by Ninhydrin 
test (Sigma-Aldrich) as well as on MALDI-TOF. The resin was collected on a fritted peptide synthesis filter 
and washed with DCM, Methanol and air-dry.  
2.6.3 Cleavage of the Peptide from the Resin 
The peptide was cleaved from the resin using trifluoracetic acid (TFA) (Chem Impex)/ 
triisopropylsilane (TIS) (Sigma)/ 3,6-dioxa-1,8-octanedithiol (DODT) (Sigma)/water (92.5:2.5:2.5:2.5) with 
incubation at RT for 4 hours, and the resin was filtered off. The filtrate containing the crude peptide was 
precipitated with cold ether, and collected by centrifugation. The supernatant was discarded and the 
peptide was dissolved in CH3CN (Fisher HPLC Grade) and water with 10% acetic acid (Fisher certified ACS 
PLUS) (1:1) followed by freezing and lyophilization.  
2.6.4 Purification by HPLC 
The lyophilized peptide generally dissolved in 50 % CH3CN or DMSO and purified by reverse phase 
HPLC using a Shimadzu Prominence system. For small scale, the purification was performed under 
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analytical condition: column, Vydac 218TP5410 4.6 × 100 mM; Solvents: A=water/0.1% TFA, 
B=CH3CN/0.1% TFA) flow rate, 0.44 mL/min; gradient, 10 min at 10 % B, 30 min at 10–100 % B. Injection 
occurred at 5 minutes and the absorbance was monitored at 443 nm.  For large-scale purification we used 
semi-preparative column following conditions: column, Vydac 218TP52210 22 × 100 mm; flow rate, 10 
mL/min; the other parameters are similar to the ones used for the analytical column. HPLC fractions were 
analyzed on MALDI-TOF. Fractions with the desired product were collected, frozen and lyophilized.  
2.6.5 Cy l z      w    α-α’-dibromo-m-xylene in Solution 
A reaction of a 50 mL final volume was set up in a 100 mL oven-dried flask, which was charged 
with water (15 mL) and acetonitrile (15 mL) and was deoxygenated by bubbling Argon for 10 min. Then, 
20 mM ammonium bicarbonate (5 mL of 200 mM, pH 8.6), 200 μM tris-carboxyethylphosphine (TCEP) (10 
mL of 1 mM) in water and peptide (10 mg, 3.5 μmol) were added and the reaction was kept under argon. 
After 60 min, 1.1 mM of α-α’-dibromo-m-xylene linker (5 mL of 11 mM) in CH3CN was added. The reaction 
was incubated at RT and monitored by MALDI-TOF. After the cyclization is completed, the reaction was 
frozen and lyophilized. The resulting white powder was dissolved in the appropriate solvent and purified 
by reverse phase HPLC as described above. 
2.6.6 Cysteine Protecting Group Removal to Prepare for Cyclization on the Solid Phase 
For this part we used Fmoc-S-tert-butylthio-L-cysteine as building block instead of Fmoc-(L)-
Cysteine(Trt)-OH during the synthesis of the peptides on SPPS.  To remove the protecting group: in a 15 
mL falcon tube, we added 100 mg of dried peptide, 5.1 mL DMF, 100 mM NH4HCO3 (600 μL of 1M in 
water), and 50 mM DTT (300 μL of 1M in DMF) and the reaction was deoxygenated by bubbling Argon for 
2 minutes. The reaction was allowed to proceed for 2.5 hours at 55 °C and the resin was collected on a 
fritted peptide synthesis filter tube, the solution of the reaction was removed using vacuum, washed three 
times with DCM and methanol, and air-dried for 5 min. The completion of the reduction was monitored 
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by analytical test cleavage and MALDI-TOF. 0.5 – 1 mg of the above resin was transferred into a 0.6 μL 
microcentrifuge tube and 100 μL of a cleavage cocktail containing trifluoracetic acid (TFA) (Chem Impex)/ 
triisopropylsilane (TIS) (Sigma)/ 3,6-dioxa-1,8-octanedithiol (DODT) (Sigma)/ water (92.5:2.5:2.5:2.5) was 
added. The tube was tumbled for 40 minutes at RT. The resin was filtered off by using Pasteur pipette 
glass with cotton.  The filtrate containing the crude peptide was precipitated with 200 μL of cold ether, 
and collected by centrifugation for 5 min at 10,000 ×g at RT. The supernatant was discarded and the 
peptide was dissolved in an appropriate solvent and analyzed by MALDI-TOF. 
2.6.7 Cyclization of the P       w    α-α’-dibromo-m-xylene on the Resin 
In a 15 mL test tube with a final volume of 5 mL DMF, 50 mg of dried peptide resin that has two 
fully deprotected cysteine residues, 20 mM of (NH4)2CO3 (40 μL of 2.5 M in water), 200 μM of TCEP (125 
μL of 8 mM), and 11 mM of α,α′-dibromo- m-xylene (1.375 mL of 40 mM in DMF) were added.  The 
reaction was allowed to proceed for 1-2 hours at 55 °C. The cyclization reaction was monitored by 
analytical cleavage and MALDI-TOF as above and the resin was collected and washed as above. Then, the 
peptide was labeled with 5(6)-carboxyfluorescein, cleaved and HPLC purified as described above. 
2.7 MALDI-TOF Analysis 
Samples were prepared for analysis by 1:1 dilution in a 1:0.99:0.01 CH3CN:H2O:TFA solution containing 10 
mg/mL α-cyano-4-hydroxy-cinnamic acid (CHCA). After spotting on the sample plate, samples were 
allowed to co-crystallize by slow evaporation at RT. Samples resulting from translation reactions were 
desalted and concentrated with ZipTipC18 Pipette Tips (Millipore) according to the manufacturer’s 
protocol. 
2.8 KD Determination Using Bead Capture of In Vitro Translated Peptides. 
35S-Met labeled peptide was incubated with GST-XRCC4157 with different concentrations in 20 μL binding/ 
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wash buffer (125 mM Tris, 150 mM NaCl, pH 8) at room temperature for 1 hour. Each solution was then 
added to 40 μL pre-equilibrated glutathione magnetic beads (Pierce) and tumbled at room temperature 
for 1 hour. The supernatant was removed and the beads were washed with binding/wash buffer (2 x 40 
μL). The radioactivity of the supernatant and wash solutions was measured by scintillation counting as 
unbound fractions. 40 μL glutathione elution buffer (250mM Tris pH 8.8, 500mM NaCl, 100mM 
glutathione, 1% Triton X-100) was added to each tube and tumbled for 1 hour. The supernatant was 
removed and the beads were washed with 40 μL binding/wash buffer. The radioactivity of the supernatant 
and this wash solution was measured by scintillation counting as bound fractions. To account for 
nonspecific binding to the beads, the measured radioactivity of the fraction containing no GST- XRCC4157 
was subtracted as background from the measured radioactivity of the trials containing GST- XRCC4157. The 
subsequent background-corrected bound value was divided by the total counts (bound + unbound 
fractions) to determine the percent of peptide bound to GST- XRCC4157 for each trial. Results were 
analyzed using SigmaPlot software and the KD was determined using a dynamic curve fit. 
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3. RESULTS 
 
 
3.1 NHEJ is Tolerant of a Substrate Containing Tg Near a DSB End  
  Tg is a major product of free radical damage to DNA, and will often occur at or near the terminus 
of a radiation-induced DSB.  Because Tg is nonplanar, it induces severe distortion in DNA structure (Aller 
et al., 2007).  Classical NHEJ, however, is capable of joining mismatched overhangs as well as a variety of 
other noncomplementary end structures (Gu et al., 2007; Tsai et al., 2007).  To determine whether Tg 
poses a barrier to ligation in the context of NHEJ, internally labeled blunt-ended substrates were 
constructed (Figure 3.1) with Tg as the first, second or third base from the 3′ terminus of one DNA end 
(Tg1, Tg2 and Tg3, respectively); the opposite end was blunt but unmodified.  End joining of these 
substrates was detected by subsequent cleavage with NdeI and PstI, which release labeled and unlabeled 
fragments, respectively, from opposite ends of the substrate.  For Tg-containing samples, the 19-mer 
corresponding to unjoined substrate migrates as a doublet, reflecting different stereoisomers of Tg. 
To assess whether Tg was a barrier to NHEJ, each of the four blunt-end substrates was incubated 
in whole-cell extracts of XLF-deficient Bustel fibroblasts (note: this work of Figure 3.2 was done by Duaa 
Bafail (a former Master student)).  For the unmodified, blunt-ended substrate, end joining was completely 
dependent on addition of purified recombinant XLF, and the only detectable products were the expected 
44-base head-to-tail and 36-base head-to-head products of direct blunt-end ligation, each of which 
precisely comigrated with synthetic markers of the same sequence (Figure. 3.2A, lanes 22-28). 
Unexpectedly, the Tg3 substrate (lanes 15-21) yielded, in addition to apparent 36- and 44-base products, 
a third product migrating as a slightly diffuse band above the 36-mer band (labeled as 36Tg).  Treatment  
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Figure 3.1.  Tg-containing DSB substrates.  A.  Construction of modified substrates from short, end-
labeled (*) Tg-containing duplexes and a fragment of pUC19.  B.  Terminal structures and sequences 
of the substrates.  C.  Formation of head-to-tail and head-to-tail end joining products, and their 
detection as fragments of NheI/PstI cleavage.   
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of the DNA with EndoIII after incubation in extracts but before NdeI/PstI cleavage (lane 18) eliminated 
most of this band, suggesting that it represents a 36-base head-to-head ligation product in which Tg is still 
present.  This Tg-containing 36-mer migrates more slowly than the unmodified 36-base product, which 
migrates anomalously fast because it is palindromic and can snap back into a hairpin upon 
denaturation/renaturation.  The Tg apparently disrupts hairpin formation and thereby decreases the 
electrophoretic mobility, providing a convenient indication of the extent to which head-to-head end 
joining products still contained the Tg base.    
In addition, EndoIII treatment eliminated about half of the 44-base product, suggesting that, as 
with the 36-base product, Tg was still present in some but not all of the ligated 44-base products.  As 
further confirmation that some of the Tg had been excised and replaced with thymine, the experiment 
was performed with ddTTP added to the extracts in place of dTTP, to arrest excision repair as a 
nonligatable intermediate.  For samples with ddTTP, the unsubstituted 36-base product from Tg3 was 
largely eliminated, confirming that it arose from excision repair of a Tg-containing ligation product (lane 
21).  The unmodified and Tg3 substrates yielded approximately the same level of 44-base product (22.1% 
vs 19.2%), and the sum of the Tg-substituted and unsubstituted 36-base products from Tg3 (6.3% and 
5.9%, respectively) was equal to the yield of single 36-base product from the unmodified substrate 
(11.6%), indicating that overall, Tg at the third position from a DNA end conferred little or no inhibition of 
NHEJ. 
3.2 Tg as the Terminal or Penultimate Ba          3′ E        DSB      Barrier to NHEJ    
In contrast to the efficient blunt-end ligation seen with the Tg3 substrate, the Tg1 and Tg2 
substrates yielded only a trace of 44-base product, approximately 1-2% of the total substrate or about 
tenfold less than Tg3 (Figure 3.2A, lanes 1-14).  Moreover, Tg1 and Tg2 yielded no detectable 36-base 
head-to-head joining product.   These results indicate that Tg as the terminal or penultimate base consti- 
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Figure 3.2.  Effect of Tg on joining of blunt-ended substrates by NHEJ.  The site-specifically labeled 
(*) substrates shown, either unmodified or containing Tg at the first, second or third position from the 
terminus of the labeled end, were incubated in XLF-deficient BuS extracts, supplemented with XLF 
(100 nM), Artemis (80 nM), and/or ddTTP in place of dTTP as indicated, for 6 hr at 37°C.  The samples 
were deproteinized, in some cases treated with EndoIII, then cut with NdeI and PstI and analyzed on 
denaturing gels.  Lanes marked “M” contain 5′-end-labeled 36- and 44-base oligomers of the sequence 
expected for blunt-end ligation products.  Bar graphs show yield of specific products of the indicated 
substrates and error bars indicate mean ± SEM for 4 replicate experiments.   
(Note: this work of Figure 3.2 was done by Duaa Bafail (a former Master student)) 
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tutes a major barrier to blunt-end ligation in NHEJ when present at one end of a DSB, and an absolute 
barrier when present at both ends.  One possible mechanism for resolution of such a barrier would be 
trimming of the Tg by Artemis, an endonuclease that associates with DNA-PK and is activated by that 
association.  As shown previously, there is insufficient Artemis in whole-cell extracts to trim canonical 
Artemis substrates such as 3′ overhangs of DSBs.   For the Tg-containing substrates, added Artemis did 
not detectably increase trimming beyond the low level already seen in the unsupplemented extracts 
(Figure 3.2A, lanes 7, 14, 20 and 26).  Nevertheless, for the Tg2 substrate only (lane 14), addition of Artemis 
resulted in a twofold increase in the yield of ligated product (1.48±0.08% vs. 0.77±0.07%, N=3), 
accompanied by a slight decrease in its length (~2 bases, based on its mobility). These results suggest that 
Tg near a DSB 3′ terminus can be trimmed by Artemis, albeit inefficiently.  
3.3 Ligation of Tg-Containing Substrates Does Not Require Prior Tg Removal   
For the Tg3 substrate, EndoIII treatment prior to restriction nuclease digestion reduced the yield 
of 44-base product, but for the Tg1 substrate in particular (Figure 3.2B), EndoIII appeared to have little if 
any effect.  Although this result could be explained by a replacement of Tg by normal thymine in all the 
Tg1 ligation products, an alternative possibility is that only the Tg-containing strand was ligated, and the 
remaining nick in the opposite strand prevented EndoIII from acting.  To assess the presence of Tg without 
regard to the status of the complementary strand, end joining products generated in extracts containing 
either dTTP or ddTTP were cut with NdeI and PstI, then denatured, and annealed to an excess of a 44-base 
oligomer complementary to the expected ligation product of the labeled, Tg-containing strand.  The 
annealed products were finally treated with EndoIII (Figure 3.3).  Under these conditions, EndoIII reduced 
the yield of 44-base product from the Tg1 and Tg2 substrates by half, and from the Tg3 substrate by 30%.  
Thus, the NHEJ machinery was clearly capable of ligating all three Tg-containing substrates, albeit 
inefficiently, even ligating a 3′-terminal Tg to a blunt end.    These results also exclude the possibility that  
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Figure 3.3 Presence of Tg in end joining products.  Tg-containing or unmodified substrates were 
incubated for 6 hr in Bustel extracts supplemented with XLF and ddTTP as indicated.  Samples were 
deproteinized and cut with NdeI and PstI, then denatured and annealed to 44-base complements of 
the expected head-to-tail ligation products and treated (or not) with EndoIII prior to denaturing gel 
electrophoresis.  Bar graphs show the yield of 44-base products in each case (mean ± SEM for 3 
independent experiments).    
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the apparent ligation of Tg1 and Tg2 substrates was the result of contamination with a small fraction of 
the corresponding unmodified substrates.  As expected, EndoIII had no effect on yield of products from 
the unmodified substrate.  For all of the Tg-containing substrates, substitution of ddTTP for dTTP likewise 
reduced the yield of ligation products dramatically, and also eliminated most of the EndoIII-resistant 
ligation products (Figure 3.3); the remainder may be due to some residual dTTP in the extracts.  This result 
shows that Tg was sometimes excised and replaced with thymine, although it does not distinguish 
whether such replacement occurred before or after blunt-end ligation of the DSB.  In the case of the Tg3 
substrate, this question was addressed by substituting ddCTP for dCTP during incubation in the extracts.  
If Tg were either trimmed off by a nuclease or removed by base excision repair prior to ligation of the DSB, 
the two 3′-terminal bases attached to it would presumably be lost as well, so that a blunt-end ligation 
product could only be formed by re-synthesis with dCTP and dTTP.  Thus, the finding that ddCTP did not 
reduce the yield of blunt-end ligation product (Figure 3.4A, lane 9 and Fig 3.4B, lane 8) suggests that most 
if not all ligations of the Tg3 substrate occurred with Tg still present.   
3.4 An Initial Delay in Ligation is Dependent on Tg Position 
To further investigate the order of Tg excision and DSB ligation, samples were taken at various 
times after addition of substrate to the extract.  For the Tg3 substrate, ligated products began to 
accumulate rapidly after an initial delay of about 30 min, but the Tg-containing 36Tg fragment 
accumulated much faster than the thymine-containing 36-base fragment (Figure 3.4A and 3.4C).  These 
data are consistent with a mechanism wherein ligation preceded Tg removal and replacement, so that at 
later times continuing ligation was approximately balanced by slow excision of Tg from the ligated 
product, resulting in a steady-state level of the 36-base Tg-containing ligation product (36Tg).  Thus, this 
result lends further support to the inference, from ddCTP trapping experiments, that ligation precedes Tg 
removal and replacement in formation of the unmodified (thymine-containing) 36-base product.   There   
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Figure 3.4.  Time course for Tg3 and Tg1 end joining and effect of dideoxynucleotides.  A. and B.  Tg3 
was incubated in extracts containing ddTTP, ddCTP and/or XLF for the times indicated, then cut with 
NdeI and PstI and analyzed as in Fig. 2.  One sample in (A.) was treated with EndoIII prior to NdeI/PstI 
cleavage, as in Fig. 3.2.  Asterisk (*) indicates addition of a mutant XLF with an L115A mutation.  C. 
Quantitative analysis of Tg3 ligation in the presence of dNTPs, derived from three replicates of the 
experiment shown in (B.).  D.  Time course of formation of end joining for Tg1.  The Tg1 substrate was 
incubated in extracts, with XLF added either at the start of the reaction (●) or after 2 hr incubation 
(□).  Reaction conditions were as in Fig. 3.2.    
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was, however, an initial delay of about 30 min before a significant level of end joining products appeared 
(Figure 3.4C).  For the Tg1 substrate, a longer delay of nearly 2 hr was seen (Figure 3.4D).  However, when 
extract and substrate were preincubated for 2 hr in the absence of XLF, end joining began immediately 
upon XLF addition, suggesting that there was some prejoining process that did not require XLF but that 
either proceeded more slowly with the Tg1 substrate, or was only essential for the Tg1 substrate.      
3.5 Mutations in XLF at its Interface with XRCC4 Reduce or Eliminate Ligation 
Previous X-ray crystallography shows that XLF binds to XRCC4 via a “leucine lock” motif wherein 
Leu115 of XLF slips into a hydrophobic pocket in XRCC4 (Hammel et al., 2011; Ropars et al., 2011).  
Moreover, an L115A mutation eliminates detectable XLF-XRCC4 binding, suggesting that the leucine lock 
is essential for this interaction.  To assess whether disruption of XRCC4-XLF interaction would differentially 
influence end joining of Tg-containing substrates, each of the substrates were incubated in extracts 
containing no XLF, wild-type XLF, or XLF wherein Leu115 was replaced with either Ala or Asp (Figure 3.5).  
The L115A mutation decreased ligation of all substrates, by roughly seven-fold, reducing ligation of Tg1 
and Tg2 to near the lower limit of detection; nevertheless, a trace of ligation of the Tg1 substrate could 
be seen.  A less conservative L115D mutation completely eliminated ligation of all five substrates.  These 
results suggest that XLF-XRCC4 interaction is essential for end joining but that the L115A mutant still 
retains some interaction with XLF.  However, there was no evidence that mutations in XLF differentially 
affected ligation of Tg-containing substrates.  Moreover, the 14-mer band corresponding to Tg excision 
from the Tg5 substrates was equally intense with or without added XLF, suggesting that the putative XLF-
XRCC4 filament did not protect Tg in the unligated substrate from excision by BER.  
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Figure 3.5.  Effect of L115 mutations in XLF on end joining.  Tg-containing substrates were incubated 
in extracts complemented with the indicated normal or mutant XLF proteins (100 nM) for 6 hr, cut 
with NdeI and BstI and analyzed on denaturing gels.  Graph shows abundance of the 44-base head-to-
tail ligation product.  There was no detectable product in samples containing either no XLF or the 
L115D mutant.   
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3.6 Development of a Diverse Peptide Libraries Composed of Cyclic Peptides to Inhibit XRCC4-XLF 
Interaction  
We used the mRNA display technique to synthesize libraries of mRNA-peptide fusions to inhibit 
the XRCC4-XLF interaction (Roberts & Szostak, 1997).   In order to find tight-binding peptides, we designed 
five libraries to contain cyclic sequences of a variety of ring sizes.   The complete structure of each DNA 
library is summarized in Figure 3.6. The libraries were constructed to contain a 12 random amino acids 
region with two fixed cysteines at different positions to ensure that we have cyclic peptides with different 
ring sizes. This will allow XRCC4157 to “choose” the most appropriate scaffold with which to bind. Also, we 
used the NNS (S=C/G) codon in the random region to decrease the prevalence of stop codons as compared 
to NNN. For cyclization, we focused on the well-established and robust bis-bromomethylbenzene 
chemistry, which covalently cyclizes peptides with two cysteines (Dewker et al., 2009; Guillen Schlippe et 
al., 2012; Timmerman et al., 2005).  
3.6.1 In Vitro Selection 
The formation of mRNA display natural cyclic peptide library started by transcription of five DNA 
templates that encode peptides with 12 random amino acids interspersed with two cysteine residues 
(Figure 3.7).  Following transcription, the five mRNA libraries were combined together and photo cross-
linked to an oligonucleotide containing puromycin at its 3 end.  Then, the combined mRNA libraries were 
translated on a 5 mL translation scale in the PURE translation system (Shimizu et al., 2001) with 20 natural 
amino acids.  After that, mRNA peptide fusions were immobilized on an oligo-dT column and cyclized using 
dibromoxylene.  In addition to giving a simple means for cyclization, these two processes were performed 
to remove peptides that were not conjugated to their mRNAs, and mRNAs that were not photocrosslinked 
by psoralen. After that, the peptide-fusions were reverse transcribed to create cDNA for PCR and to 
eliminate any unwanted RNA secondary structures.  Then, the mRNA-peptide fusions were purified using  
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Figure 3.6 DNA libraries structure. The peptide sequence encoded by the library (shown above) has 
an N-terminal fixed cysteine and another cysteine after a random region of 2, 4, 6, 8 or 10 amino acids 
encoded by a degenerate codon NNS (S=C, or G).  It has a flexible linker with two out of frame stop 
codons; GlySerGlySer-LeuGly. It has 6xHis tag at the C-terminus for Ni-NTA purification.  
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Figure 3.7. In vitro selection process search for XRCC4-XLF inhibitors. We started with DNA libraries 
as described in Figure 3.6. After mRNA−peptide fusion formation, peptides were cyclized with 
dibromoxylene. Purified mRNA−peptide fusions were reverse transcribed and purified on Ni-NTA 
beads before being selected for binding to GST-XRCC4157 fusion immobilized on magnetic beads. 
Unbound peptides were washed away, and bound peptides were PCR amplified, and carried through 
the subsequent round of selection.  
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a Ni-NTA column in order to remove the truncated mRNA peptide fusions which were dialyzed into 
selection buffer. After this procedure, 1.44 pmols of peptides library were created, corresponding to a 
diversity of 870 billion unique peptide sequences. 
In the selection step of the first round, we first incubated our library with GST protein (not fused 
to XRCC4) on magnetic beads in order to remove all non-specific peptide inhibitors that bind to the GST 
or glutathione magnetic beads.  Then, the flow through and washes with high counts were collected and 
bound to WT GST-tagged XRCC4157 fragment.  This fragment includes the complete head domain known 
to contain the XLF interface but lacks the C-terminal DNA ligase IV-binding region that could interact with 
the mRNA component of our mRNA-peptide fusions.  Those peptides that bound to WT GST-XRCC4157 
were captured on the glutathione magnetic beads.  Then, the beads were washed and suspended in 
selection buffer and the percentage of the 35S-labeled peptides bound to the resin was measured to be 
2.1% (0.03 pmole).  The DNA-mRNA duplex fused to the XRCC4-captured peptides was amplified by PCR. 
This signifies the end of the first round and the resulting DNA from this round was in vitro transcribed and 
then new mRNA-peptide fusions were formed to take through the subsequent rounds.  The recovery was 
calculated at the end of each round (Figure 3.8). From round five, we started to increase the stringency of 
washing during the selection by using a technique known as Continuous-Flow Magnetic Separation (Olsen 
et al., 2011). After binding the peptide-fusions to the immobilized protein, we continuously washed with 
washing buffer at a rate of 0.5 mL per minute for 10 minutes in order to remove those peptides which are 
not very tight binders and leave those with high binding affinity to the protein. 
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A. 
 
 
First Rd Second Rd Third Rd Fourth Rd Fifth Rd Sixth Rd Seventh Rd 
Purification 
(input) 
1.44 pmole 0.35 pmole 0.49 pmole 0.18 pmole 0.436 pmole 0.21 pmole 0.53 pmole 
GST-XRCC4
157
 
(output) 
0.03 pmole 
(2.08%) 
0.004 pmole 
(1.14%) 
0.011 pmole 
(2.24%) 
0.022 pmole 
(12.2%) 
0.051 pmole 
(11.7%) 
0.022 pmole 
(10.48%) 
0.021 pmole 
(3.96%) 
 
B.  
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Figure 3.8. In vitro selection results. Progress of the selection measured by the percentage of the total 
35S-Met labeled peptides. A) Shows the amount of peptide fusions after purification added to the 
selection step (input) compared to the remained bound to the beads. B) Graphical representation of 
percentage recovery from (A). Note: the decrease in the percentage of the recovery after round seven 
was due to bead lost during the washing step.   
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3.7 Sequencing 
After the seventh and final round, cDNAs corresponding to the selected mRNA−peptide fusions 
were sequenced.  The sequencing result shows that the peptides could be arranged into five families, 
which we named 7.1-7.5 based on their relative abundance (Figure 3.9).  To ensure the winners of the 
seventh round were present and enriched during the selection from round to round, we sequenced cDNA 
from round 3 to 6 using Second Generation Sequencing (Figure 3.10 and Figure 3.11). Indeed, the Second 
Generation Sequencing result showed that the winners of round seventh were present from the beginning 
and were enriched especially from round 4 to 5 and from round 5 to 6. However, they were not the 
winners of round three and did not enrich very well from 3 to 4; nevertheless, the number of sequences 
of these peptides were high in these rounds. The reason why we see significant enrichment from round 4 
to 5 and 5 to 6 is because at round five we started to increase the stringency of washing during the 
selection (Olsen et al., 2011).  The fact that these peptides survived the continuous washes suggests that 
the winners of round seven are high affinity binders. 
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Family 7.1 Family 7.2 Family 7.3 
Family 7.4 
Family 7.5 
Figure 3.9. Sequencing result. After round seven, cDNA from the library pool was cloned and 
sequenced giving the 81 sequences shown. Similar sequences were arranged into five families. 
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Figure 3.10. Second generation sequencing result. cDNA from round 3, 4, 5 and 6 were sequenced by 
Second Generation Sequencing. The graph shows the enrichment of the selected peptides from round 
to round.  
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Round Three Round Four Round Five Round Six 
MCRGARSTTPVEHRR* MCRGARSTTPVEHRR* MCRGARSTTPVEHRR* MCLCGTRRRGARRGAV 
MCRKTQTVCPVVNRNGS MCAVCPATWLCVMREGS MCGLPMTELVCPCRMGS MCSWMWRIETCGMILGS 
MFCDGFYACYMDVGSGS MCRVLKRRALSSCLVGS MCAVCPATWLCVMREGS MCWEVVGEILCVWSLGS 
MCGLPMTELVCPCRMGS MCRKTQTVCPVVNRNGS MCRKTQTVCPVVNRNGS MCGVGVVRVCRQRGGS 
MCRVLKRRALSSCLVGS MCGLPMTELVCPCRMGS MCWKCQCMCLHGILRGS MCRGARSTTPVEHRR* 
MCAVCPATWLCVMREGS MCRYFSLWLHEPTGCAGGS MCLCGTRRRGARRGAV MCGLPMTELVCPCRMGS 
MCKFIKFFNFRYRHGSGS MCWKCQCMCLHGILRGS MCWEVVGEILCVWSLGS MQLDVAHRDVRDDPR* 
MCWKCQCMCLHGILRGS MCAVCPVTCVSFCSSV MCRVLKRRALSSCLVGS MCAVCPATWLCVMREGS 
MCLVTYVVCPMTRESGS MWRMCLCPAAASSV MCSWMWRIETCGMILGS MCGKMEGRSVKRA*RGS 
MCLCGTRRRGARRGAV MCRYFSLWLHEPTGCAGS MCAVCPVTCVSFCSSV MCWEVVGILLCARANGS 
MWRMCLCPAAASSV MCQMNIERMENR*GTV MCRGARSTTPVEHRW* MCWEFMGRSPCLWARGS 
MCSWMWRIETCGMILGS MCFCAIKVAQRSSADVPGS MCAVCPATSLSLIVTGS MCRKTQTVCPVVNRNGS 
MCAVCPVTCVSFCSSV MCRGARSTTPVEHRW* MCQMNIERMENR*GTV MCLCGTRRRGARRGVV 
MCWEVVGEILCVWSLGS MCRGLTCCTLLAAKKGS MWRMCLCPAAASSV MCWEVVGISLCARANGS 
MCPKFMLNVCPFVRLWV MCRVLKRRALSSCLVV MCGVGVVRVCRQRGGS MCVPCKGRSVKRA*RGS 
MCQMNIERMENR*GTV MCAVCPATSLSLIVTGS MCRGARSATPVEHRR* MCCWWVLIFAAACGAV 
MCRGLTCCTLLAAKKGS MCAT*ICLIQRRLENGS MCWEFMGRSPCLWARGS MCWKCQCMCLHGILRGS 
MCAT*ICLIQRRLENGS MCWVCPQTR*SMKWFGS MCWEVVGILLCARANGS MCRVLKRRALSSCLVGS 
MCGVGVVRVCRQRGGS MCPKFMLNVCPFVRLWV MCWVCPQTR*SMKWFGS MCWEVVGEILCVWSMGS 
MCAVCPVPELDYLVGGS MCLVTYVVCPMTRESGS MCRGLTCCTLLAAKKGS MC*LTGCWEVWGTWYGS 
MCRCCRWLWTGEANMGS MCW*R*RECPCSNSNGS MCRYFSLWLHEPTGCAGGS MCDRLMVWSICFVRAV 
MCCSGGCTNHCMCLQGS MFCDGFYACYMDVGSGS MCRGARSTTPVEQRR* MCRGARSTTPVEHRW* 
MCW*R*RECPCSNSNGS MCLCGTRRRGARRGAV MCAT*ICLIQRRLENGS MCRQCGRSAATTRGV 
MCRGARSTTPVEHRW* MCRCCRWLWTGEANMGS MCRVLKRRALSSCLVV MCNVEKLRQVCIRPGR* 
MCWEVVGILLCARANGS MCWEVVGEILCVWSLGS MCRGARSTTPVEHRRE MCSWMRRIETCGMILGS 
MCWVCPQTR*SMKWFGS MCKFIKFFNFRYRHGSGS MRRGARSTTPVEHRR* MCWEVVGEILCVWSLV 
MCEKTQCMSSLRLLMGS MCAVCPVPELDYLVGGS MCGLPMTELVCPCRMV MCSWMWRIETCGMVLGS 
MCCRL*RLCQRIRYSGS MCWGEDLEGDC*KWRR* MCRYFSLWLHEPTGCAGS MCAVCPVTCVSFCSSV 
MCPWKNSKKGCELEEGS MCRGARSATPVEHRR* MCGKMEGRSVKRA*RGS MCWEALRGANCVVVIGS 
  
Figure 3.11. Top 30 sequences of round 3, 4, 5, and 6 after second generation sequencing. The 
highlighted sequences are the winners of round seven. 
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3.8 Synthesis of the Selected Peptides 
We selected a representative peptide from each family of round seven (7.1 – 7.5) as well as two 
winner’s peptides from round 3 (3.2 and 3.3) to be synthesized on solid phase peptide synthesis (SPSS). 
The synthesis of the peptides is summarized in Figure 3.12. The goal is to prepare m-dibromoxylene 
cyclized, 5(6)-Carboxyfluourecin labeled and HPLC purified peptides (Figure 3.13 and 3.14). The progress 
of the peptides synthesis is summarized in Table 3.1.  The cyclization is because we have used cyclic 
peptides during the selection for XRCC4 binders. However, we prepared linear forms as well to see the 
differences between the cyclic and linear peptides in term of binding affinity to XRCC4 protein and 
inhibition of NHEJ in cell extract assay. However, we had challenges during the preparation of our 
peptides.   
 
Figure 3.12. Peptide synthesis approaches. Synthesis of the peptides that involved (A) cyclization in 
solution or (B) cyclization on the resin. 
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Figure 3.14 MALDI-TOF analysis of Pep 7.4 and Pep 3.2. After synthesis on the solid phase, a) Pep 7.4 
and b) Pep 3.2 were labeled, cyclized and purified by HPLC and analyzed by MALDI-TOF. Expected (Exp) 
masses are [M + H]+ peaks. 
 
Figure 3.13. HPLC spectrum of Pep 7.4 
 
a b 
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Peptides Sequences SPPS Labeling Reduction Cyclization 
HPLC 
(Linear) 
HPLC 
(Cyclic) 
7.1 MCSWMWRIETCGMIL Yes 
Not 
complete 
Not 
complete 
No Yes No 
7.2 MCLCGTRRRGARRGAVAAP Yes Complete Complete Yes Yes Yes 
7.3 MCWEVVGEILCVWSL Yes 
Not 
complete 
Not 
complete 
No No No 
7.4 MCGVGVVRVCRQRG Yes Complete Complete Yes Yes Yes 
7.5 MCWEVVGISLCARAN Yes 
Not 
complete 
Not 
complete 
No No No 
3.2 MCRKTQTVCPVVNRN Yes Complete Complete Yes Yes Yes 
3.3 MFCDGFYACYMDVGS No 
Not 
complete 
Not 
complete 
No No No 
 
3.8.1 Challenges 
Peptides 7.1, 7.3, 7.5 and 3.3 are highly hydrophobic as shown in Table 3.2, and presumably as a 
consequence these peptides presented severe difficulties in synthesis and purification, as shown for Pep 
7.1 in Figure 3.15. Also, we could not get pure product of crude peptide 3.3 which might be due to the 
presence of aspartic acid followed by glycine (X-Asp-Gly-X) in its sequence in which these two amino acids 
are difficult to be coupled. Since this peptide was not one of the winners of round seven and we were not 
successful in getting pure product, we stopped working with it. To overcome the hydrophobicity of these 
peptides, we replaced m-dibromoxylene with 1,3-bis(bromomethyl)benzyl 2-[2-(2-
methoxyethoxy)ethoxy]acetate which was prepared by attaching a hydrophilic linker (2-[2-(2-
methoxyethoxy)ethoxy]acetic acid) to 1,3,5-tris(bromomethyl)benzene (Figure 3.15) using the procedure 
outlined by Dewkar and Hartman (2009). This substitution helped to some extent but not very 
significantly.  The other approach that we have used to increase the solubility of these peptides is to attach 
Table 3.1. Summary of peptides synthesis. 
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a poly arginine (R9) with a GS linker at the C-terminus of each peptide (Table 3.3) and to this product 
attach an 6-Aminohexanoic acid to the N-terminus of these peptides as a linker to improve the efficiency 
of labeling with 5-FAM. We also made truncated peptides. All of that was helpful but still not enough to 
get a soluble cyclic peptide of 7.1, 7.3 and 7.5 that can be purified by HPLC. 
 
 
 
 
 
 
 
 
 
 
 
Peptides Sequences 
Hydrophilic 
residues 
Hydrophobic 
residues 
Net Hydro-
phobicity (%) 
7.1 MCSWMWRIETCGMIL RE MWMWIMIL 40.00 
7.2 MCLCGTRRRGARRGAVAAP RRRRR MLV -6.67 
7.3 MCWEVVGEILCVWSL EE MWVVILVWL 46.67 
7.4 MCGVGVVRVCRQRG RRR MVVVV 13.33 
7.5 MCWEVVGISLCARAN ER MWVVIL 26.67 
3.2 MCRKTQTVCPVVNRN RKR MVVV 6.67 
3.3 MFCDGFYACYMDVGS DD MFFYYMV 33.33 
Table 3.2. Percentage of the hydrophobicity of each peptide. 
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Figure 3.15. MALDI-TOF analysis of Pep 7.1 (MCSWMWRIETCGMIL). a) Analysis of linear Pep 7.1 after 
labeling with 5-FAM. Beta-alanine was attached at the N-terminus as a linker to facilitate labeling. It 
shows that not all of the peptide was labeled and it shows some truncations. b) Analysis of labeled 
Pep 7.1 after HPLC. The spectrum shows impure peptide.  c) Analysis of linear Pep 7.1 in which we 
used Fmoc-S-tert-butylthio-L-cysteine as building block instead of Fmoc-(L)-Cysteine(Trt)-OH.  d) 
Reduction of the thiol groups of the cysteines of Pep 7.1 while it is on the resin with 50 mM DTT and 
100 mM NH4HCO3.  e) Cyclization of Pep 7.1 (d) on resin with α,α′-dibromo- m-xylene.  f) HPLC for 
linear Pep 7.1 labeled with 5-FAM. All expected (Exp) masses are [M + H]+ peaks. 
 
a b 
c d 
e f 
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Figure 3.16. The Synthesis of 1,3-bis(bromomethyl)benzyl 2-[2-(2-methoxyethoxy) 
ethoxy]acetate. Note: the linker was synthesized by Dr. Hartman 
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  Full length peptides Truncated peptides 
7.1 6-AminoHex-MCWMWRIETCGMIL-GS-RRRRRRRRR 6-AminoHex-CSWMWRIETC-GS-RRRRRRRRR 
7.3 6-AminoHex-MCWEVVGEILCVWSL-GS-RRRRRRRRR 6-AminoHex-CWEVVGEILC-GS-RRRRRRRRR 
7.5 6-AminoHex-MCWEVVGISLCARAN-GS-RRRRRRRRR 6-AminoHex-CWEVVGSLC-GS-RRRRRRRRR 
 
  
Table 3.3. Modification of the peptides to increase their solubility. Full length and truncated Pep 7.1, 
7.3 and 7.5 were synthesized on SPPS. GSRRRRRRRRR was attached to the C-terminus.  
6-Aminohexanoic acid was attached to the N-terminus of these peptides. 
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3.9 Determination the Binding Affinity of the Selected Peptides to XRCC4 Protein 
3.9.1 Fluorescence Polarization 
We used a fluorescence polarization (FP) assay to determine the Kd of our peptides. Generally, 
the concentration of the fluorescently labeled peptides was kept constant and incubated with an 
increasing protein concentration. FP requires high protein concentrations to produce a full binding curve. 
The Kd of the linear Pep 7.1 and Pep 7.2 were 16.78 µM and 18.77 µM, respectively Figure 3.17. 
Unfortunately, the reported results of the above peptides could not be reproduced. The cyclic Pep 7.2, 
7.4 and 3.2 failed to show any binding affinity to XRCC4 protein. We could not measure the binding affinity 
of the cyclic Pep 7.1, 7.3 and 7.5 because we could not synthesize full length, cyclize, labeled and HPLC 
purified of these peptides 
3.9.2 Scintillation-Based Kd Determination 
The other approach we have used to determine the binding affinity of our peptides is by 
translating our peptides in vitro and measuring the Kd based on the scintillation count of 35S-methionine-
labeled peptides (Railey et al., 2015; Horiya et al., 2014). We have saved clones in glycerol stocks in 96 
well plate when we sent the cDNA after round seven for sequencing. Therefore, we picked up some 
clones, sent for sequencing, in vitro transcribed and in vitro translated with 35S-methionine (Figure 3.18). 
The translation yields and the input count of the selected peptides were not high and could not generate 
binding results of this experiment (Figure 3.19). Then, we ordered DNA templates of these peptides with 
an optimization of the N-terminus, but it did not help. One possible reason is that Pep 7.1, 7.3 and 7.5 are 
highly hydrophobic which might lead to aggregation and prevent the His tag from binding to Ni-NTA. We 
have tried detergent to prevent such aggregation. Unfortunately, it did not improve the translation yield 
significantly. 
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Figure 3.17. Fluorescence polarization data of Pep 7.1 and Pep 7.2. Anisotropy measurements were 
analyzed in Sigma Plot where curves were fit to the Four Parameter Logistic Curve to determine the Kd 
values. Each reaction contained 20 nM FAM-labeled peptides incubated with different XRCC4157 
protein concentrations. Error bars denote the standard deviation from the mean of duplicate 
experiment in a single plate. 
K
d
 = 16.78 µM ± 0.99 Kd = 18.77 µm ± 2.33 
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A 
B 
Figure 3.18. Preparation for scintillation-based Kd determination. A) General scheme that shows how 
the clones are picked up and prepared for binding study. B) Sequence verification for the selected 
clones.  
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Figure 3.19. In vitro translation of Pep 7.1.  a) In vitro translation of Pep 7.1 (from clone number 80) 
compared to that of a high-yielding peptide Dbell in three different conditions: A. Bind under 
denaturing condition and wash and elute under native conditions. B.  Suspend the peptide with DMSO 
on the column and transfer to new tube; then wash and elute under native condition. C. Bind and wash 
with Tris-buffered saline (TBS) and elute with 1%TFA. b) In vitro translation of Pep 7.1 (from ordered 
DNA template). 7.1-A and Dbell-B. Binding under denaturing condition and wash and elute under 
native condition. 7.1-B. Bind and wash with TBS + 0.2% Triton and elute with 1%TFA + 0.2% Triton.  
a) b) 
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3.10 Inhibition of NHEJ in Cell Extracts 
It has been shown that whole-cell extracts isolated from any of several patients with XLF 
mutations could not rejoin a simple-restriction cut plasmid, and about 10% of the end joining was 
detected when the cell extract prepared from patient cells was transfected with XLF cDNA (Buck et al., 
2006).  However, we have used extracts with high protein concentration and were able to detect about 
2% of end joining even in an extract with XLF deficiency (Konstantin et al., 2009).  Moreover, the end 
joining was stimulated as much as 75-fold by complementing the cell extract with XLF protein. This 
suggests that NHEJ efficiency depends on XLF protein for repairing even simple DSBs with no requirement 
for end processing. As pointed out before, XRCC4/XLF interaction is essential in NHEJ, and mutagenesis 
studies (Ropars et al., 2011; Malivert et al., 2010) showed that this interaction is disrupted by a single 
mutation on the interface between these two proteins. As pointed out in section 3.5, XLF L115D mutant 
completely inhibits EJ of modified and unmodified substrates in cell extract. Therefore, the cell extracts 
study is an excellent model to test the ability of our peptides to inhibit the interaction between XRCC4 
and XLF.  
We tested the linear form of Pep 7.1 and Pep 7.2 and cyclic form of Pep 3.2 using a simple 
restriction cut plasmid in cell extract (Figure 3.20). Initially, they showed significant inhibition to the end 
joining. Liner Pep 7.1 reduced the EJ by about 50%, liner Pep 7.2 by about 40% and cyclic Pep 3.2 by about 
80%. However, these results could not be reproduced and cyclic Pep 7.2 and cyclic 7.4 did not show 
inhibition to the EJ. The initial result that we have seen could be due to an aggregation in the extract that 
prevent the EJ rather than an actual effect of the peptides.  
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  A. 
B. 
D. 
3.20. EJ inhibition assay. A) Construction of a labeled plasmid bearing cohesive 3′ overhangs 
(−GTAC/−GTAC). B) The labeled plasmid was incubated with Pep Lin Pep 7.1 or Lin Pep 7.2 for 6 hours 
in BuS extracts supplemented with XLF. D) Similar to B except that we used Cyc Pep 3.2 that either 
dissolved in DMSO or PBS buffer. C) and E) Graph representation of B and C, respectively. 
 
C. 
E. 
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4. DISCUSSION AND FUTURE DIRECTION 
 
In mammalian cells, repair of DSBs induced by ionizing radiation, as judged either by pulsed-field 
gel electrophoresis of cellular DNA (Stenerlow et al., 2003) or by the emergence and dissolution of γH2AX 
foci (Leatherbarrow et al., 2006), is typically biphasic.  Whereas the majority of breaks are rejoined within 
1 hour, the remaining 10-20% require several additional hours.  Although most of the slow component of 
repair likely represents DSBs in heterochromatin (Goodarzi et al., 2008), the finding that DSBs formed by 
high-LET radiation are also rejoined rather slowly (Shibata et al., 2011), suggests that the chemical 
complexity of a DSB is an additional factor in increasing the time required for its repair.  Slower repair in 
turn could increase the probability that DSB ends become physically separated, leading to lethal or 
carcinogenic chromosome breaks and rearrangements. 
Complex DSBs can reasonably be assumed to comprise random combinations of fragmented 
sugars and any of a multitude of oxidatively modified bases, spread over 10-20 bp of DNA (Ward, 1988; 
Hutchinson, 1985).  Once terminal blocking groups, primarily 3′-phosphates and 3′-phosphoglycolates, are 
removed, religation of otherwise compatible ends may still be prevented by base damage, especially 
structure-distorting base lesions very close to the termini.  Tg, one of the most common oxidative lesions 
in DNA (Evan et al., 2004), is nonplanar, resulting in severe local perturbation of DNA structure (Aller et 
al., 2007), potentially rendering DSBs resistant to repair.  Although in principle these damaged ends could 
be trimmed off by the NHEJ-associated Artemis nuclease, previous work indicates that presence of Tg 
near a DSB end does not promote such trimming, but on the contrary inhibits trimming of structures that 
would otherwise be favored Artemis substrates, such as 3′ overhangs (Mohapatra et al., 2013).  On the 
other hand X4L4 can ligate diverse nonmatching ends that are not substrates for other ligases, and its 
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tolerance for mismatched ends is enhanced by XLF (Gu et al., 2007; tsai et al., 2007).  To determine the 
tolerance of NHEJ for modified structures that would occur in complex, free radical-mediated DSBs, joining 
of ends harboring Tg at various distances from the 3′ terminus was examined in Bustel whole-cell extracts.  
End joining of all substrates in this system is completely dependent on the presence of XLF as well and 
DNA-PKcs, and is blocked by a DNA-PKcs inhibitor (Baumann and West, 1998; Akopiants et al., 2009; Povirk 
et al., 2007), suggesting that it reflects exclusively classical NHEJ.  Moreover, inasmuch as these extracts 
can carry out all steps of NHEJ with very high efficiency (as much as 30-50% of free ends rejoined), they 
likely contain ample concentrations of core NHEJ proteins Ku, DNA-PKcs, X4L4 and XLF, and possibly 
additional factors that remain to be identified.   
Tg as the third base from a blunt end (Tg3 substrate) had only a small inhibitory effect on ligation 
of blunt ends by the combination of X4L4, XLF and Ku, and almost no effect on ligation in extracts.  The 
significant proportion of head-to-head ligations derived from this substrate indicates that such ancillary 
damage was tolerated even when present at both ends of a break.  Although Tg in this substrate was 
eventually replaced with thymine, presumably via BER, DSB ligation usually if not always preceded Tg 
excision, as indicated by the rapid accumulation of ligated Tg-containing products.  In the unligated 
substrate, there appeared to be minimal processing by BER, as there was little accumulation of the 2-base-
shorter fragment that would result from BER in the presence of ddTTP.   
The unligated Tg1, Tg2 and Tg3 substrates appeared to be poor substrates for BER, as judged by 
the low levels of cleavage at Tg sites, even in the presence of ddTTP (Figure 3.3).  Since the Tg1 and Tg2 
products were also poor substrates for NHEJ-mediated ligation as well as for Artemis-mediated trimming, 
such lesions when formed in cells could be quite persistent, increasing the probability of either misjoining 
to the end of a different DSB, or of a collision with a replication fork or transcription complex.  This is 
particularly true for breaks with base damage at both ends.  With the Tg1 and Tg2 substrates, there was 
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not under any condition any detectable head-to-head ligation of such DSBs.  In S and G2 phase, the 
unrepaired break could be 5’-resected by Mre11 and CtIP and thereby channeled into HRR.  However, the 
damaged 3’ end would still have to be resolved at some point in order to prime the synthesis required for 
completion of HRR.  Mre11/CtIP may also carry out more limited 5′ resection in G1 (Averbeck et al., 2014; 
Quennet et al., 2011), perhaps exposing enough undamaged 3′ overhang to promote trimming by Artemis, 
finally yielding an end more compatible with NHEJ.   
Despite the structural evidence for the importance of the leucine lock motif in stabilizing XLF-
XRCC4 interaction (Hammel et al., 2011; Ropars et al., 2011), disparate results have been obtained for the 
XLF L115A mutant.  This mutant protein showed no apparent binding to XRCC4 and little or no stimulation 
of X4L4-mediated ligation of mismatched ends (Andres et al., 2007), yet fully complemented an XLF-
deficient HCT116 cell line in terms of both V(D)J coding joint formation and end joining of a transfected 
substrate (Fattah et al., 2014).  The less conservative L115D mutant on the other hand has yielded 
uniformly negative results in all assays (Hammel et al., 2011; Ropars et al., 2011; Malivert et al., 2010), 
but the two mutants have never been compared in the same study.  The present results clearly show that 
the two mutations are not equivalent and that the L115A mutant retains some residual activity in 
promoting end joining, which appears to be sufficient to phenocopy wild-type XLF in intact cells.    
4.1 Therapeutic potential of suppressing DSB repair by targeting XRCC4/XLF interaction 
Induction of DNA damage by a radio- or chemotherapeutic agent is still a key element in cancer 
therapy.   However, the dose of DNA damaging agent that can be delivered to the cancer cells is limited 
due to the toxic side effects produced by such agents.  Exposure to cytotoxic agents also results in the 
activation of accurate or inaccurate DNA repair mechanisms that allow the survival of cancer cells leading 
to inadequate tumor response to radio- or chemotherapy (Bolderson et al., 2009).  Therefore, targeting 
the DNA repair mechanisms that are required for cancer cell survival will increase the efficiency of radio- 
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or chemotherapy.  Furthermore, since cancer cells often have disrupted DNA damage and repair 
responses, they may be more susceptible than normal cells to interference with normal repair 
mechanisms. 
The majority of ionizing radiation-induced DSBs are repaired by NHEJ in mammalian cells, which 
has raised the possibility of directly targeting the NHEJ proteins and their interactions for the purpose of 
radiosensitization of tumor cells.  DNA-PK has been shown to be a good target for radiosensitization of 
tumor cells, in that cells deficient in Ku70/80 or the DNA-PKcs are sensitive to DSBs induced by IR. The use 
of NU7441, a DNA-PK inhibitor, has shown an increase in the radiosensitivity of different cell lines and in 
xenograft models in preclinical trials (Zhao et al., 2006).  However, inhibitors of DNA-PK will also interfere 
with its roles in telomere maintenance (Gilley et al., 2001; Goytisolo et al., 2001) and immune functions 
(W. Chu et al., 2000; Dragoi et al., 2005).  Therefore, finding a more selective inhibitor is required. 
Inhibition of XRCC4 is a particularly attractive target for overcoming tumor radioresistance 
because its only known function is in NHEJ (Schaue & McBride, 2005).  Also, it has been shown that breast 
tumor cells can be radiosensitized by adenovirus-mediated overexpression of a fragment of XRCC4 that 
binds ligase IV but does not support NHEJ (Jones et al., 2005).  In addition, the interaction between XRCC4 
and XLF should be a much more susceptible target for radiosensitization because, whereas XRCC4 and 
ligase IV form a tight complex in cells, the XRCC4-XLF interaction is transient.  With any radiosensitizer, 
there will undoubtedly be some sensitization of normal tissues, and whether inhibition of NHEJ will 
ultimately improve therapeutic index is difficult to predict and will only be determined by future 
preclinical and clinical studies.  However, as many breast tumor cells have partial deficiency in HRR and/or 
upregulated NHEJ (Gudmundsdottir and Ashworth, 2006; Nagaraju and Scully, 2007; H. Wang et al., 2001; 
Zhuang et al., 2006), raising the possibility that they may indeed be sensitized more than surrounding 
tissue when NHEJ is suppressed.  Furthermore, when breast tumors treated with radiation metastasize, 
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the subsequent tumors are often highly radioresistant due to upregulation of these downstream 
pathways (Johnston et al., 2006; Das et al., 2007) raising the possibility that the therapeutic index with 
metastasized tumors could be even greater.  
Therefore, in order to inhibit the interaction between XRCC4 and XLF, a powerful technique such 
as mRNA display should be implemented.  This technique has been used to find inhibitors of protein-
protein and protein-ligand interactions (Railey et al., 2015, Schilppe et al., 2012; Getmanova et al., 2006).  
We chose mRNA display over the other selection techniques available because it possesses several 
advantages.  For example, the presence of the covalent bond between the peptide and mRNA makes it 
highly stable compared to a non-covalent bond linkage in other techniques such as the ribosome display 
(Hui and Rihe, 2011).  Therefore, in mRNA display the selection process can be performed under stringent 
conditions in order to optimize the selection of specific binders from non-specific ones.  Another 
advantage of mRNA display is the ability of producing large libraries of different unique sequences.  mRNA 
display is totally an in vitro selection technique that can produce as many as 1012-1014 unique sequences 
while other techniques that rely on an in vivo process have limitations that produces diverse sequences 
of up to 1010 only.  Another advantage of mRNA display includes the easy removal of abundant sequences 
from the starting library increasing the chance of selection non-abundant sequences.   
Therefore, we produced WT GST-XRCC4157 protein in order to use it for the selection of the peptide 
inhibitors of the XRCC4/XLF interaction.  We used truncated XRCC4 because this fragment includes the 
complete head domain known to contain the XLF interface but lacks the C-terminal DNA ligase IV-binding 
region that could interact with the mRNA component of our mRNA-peptide fusions (Ropars et al., 2011; 
Malivert et al., 2010).   
Five DNA libraries have been synthesized and we have sequenced sample clones of each library 
to find that they have the sequences as they were designed.  About a trillion mRNA-peptide variants went 
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to the selection in the first round.  We were expecting about 10 trillion unique peptide fusions to start the 
selection; nevertheless, the amount we obtained should be sufficient to find selective inhibitors.  After 
seven rounds of selection, we sent cDNA for sequencing and found a homology of five families we named 
7.1 to 7.5. Second Generation Sequencing of DNA after round 3, 4, 5 and 6 showed that the selected 
peptides were present in the first rounds and were not randomly selected in the last round. The peptides 
were significantly enriched from round 4 to 5 and 5 to 6 which could be attributed to the increase in the 
stringency of washing during the selection. Interestingly, the selected peptides except Pep 7.2 have the 
second cysteine after 8 amino acids which indicates that this ring size is the most appropriate scaffold for 
the XRCC4 protein to bind with.  The goal is to synthesize a representative peptide from each family of 
round seven as well as two peptides from round 3. The process of synthesis of Pep 7.1, Pep 7.3 and 7.5 
was not easy. These peptides are rich in hydrophobic residues. The selection of hydrophobic peptides 
might be a good sign that our peptides are attached to the hydrophobic pocket of XRCC4 protein which 
has the interface were XLF binds. Also, Pep 7.1, Pep 7.3 and Pep 7.5 have leucine residue in their 
sequences indicating the importance of leucine in binding with XRCC4.  
One approach to improve the synthesis of the hydrophobic peptides is to express them on a 
superfolder green fluorescent protein (sfGFP). It is a stable protein and produces efficient fluorescent 
chromophore that can be utilized to measure the binding affinity of the peptides by FP.  We also may start 
the in vitro selection again using XLF protein to discover peptides that can bind to the XRCC4 interface and 
inhibit their interaction. 
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